Background
==========

Atrial fibrillation (AF) is one of the most critical and frequent arrhythmias precipitating morbidities and mortalities such as hemodynamic instability, thromboembolism, and stroke, increasing hospital re-admissions and, consequently, health care costs. In general, AF negatively affects patient quality of life \[[@b1-medscimonitbasicres-23-179]\]. AF alone is associated with 1.5% to 1.9% increase in risk of mortality in a wide spectrum of ages in both genders \[[@b2-medscimonitbasicres-23-179]\]. Moreover, the situation is likely to worsen since the number of people with AF is expected to double by 2050 \[[@b2-medscimonitbasicres-23-179],[@b3-medscimonitbasicres-23-179]\].

The pathophysiological mechanism in AF is highly complex and multifactorial \[[@b3-medscimonitbasicres-23-179]\]. Prothrombotic state, inflammation, and oxidative stress may play important roles in the occurrence of supraventricular arrhythmia \[[@b4-medscimonitbasicres-23-179]\]. Introduction of practical and available diagnostic methods and their wider use allows for better identification of patients with new-onset or recurrent AF \[[@b3-medscimonitbasicres-23-179],[@b4-medscimonitbasicres-23-179]\]. Traditionally, the major focus in diagnosis and management of AF has been patient medical history, examination, and detection of AF and paroxysmal AF (PAF) using cardiac monitoring.

Complete blood count (CBC) is an important blood test routinely used in clinical practice for workup of cardiovascular diseases \[[@b5-medscimonitbasicres-23-179]\]. The relationship between blood parameters in CBC tests and clinical outcomes in patients with ST-segment elevation myocardial infarction has been well documented \[[@b5-medscimonitbasicres-23-179]\]. However, the diagnostic performance of blood parameters for AF, alone and in combination with other diseases, is still unknown.

Various studies have reported the association of hematological parameters with new-onset and recurrent AF, but the data have been largely inconclusive. This systematic review with meta-analysis sought to determine the strength of evidence in terms of the potential association between a large number of hematologic parameters that can be easily obtained using the CBC test and new-onset and recurrent AF.

Material and Methods
====================

Literature search
-----------------

A comprehensive literature search was conducted in electronic scientific databases (Medline/PubMed, Embase, Web of Science, and Google Scholar) from their inception through November 30, 2016 to identify relevant studies on the association between blood parameters in CBC tests and new-onset and recurrent AF. Predefined search terms were as follows: "white blood cell count", "WBC", "leucocyte", "neutrophil to lymphocyte ratio", "NLR", "platelet count", "mean platelet volume", "MPV", "platelet distribution width" "PDW", "red blood cell count", "RBC count", "red blood cell distribution width", "RDW", and "atrial fibrillation" or "supraventricular arrhythmia". No restrictions were applied regarding sample size of studies, language, and time of publication. To assess additional studies not indexed in common databases, all retrieved references of the enrolled studies, recent published review articles, and meta-analyses were also checked.

Study selection
---------------

Studies were included in the analysis when they met the following criteria: 1) human subjects; 2) cohort or case-control studies; 3) comparative studies between AF and non-AF-cohorts in terms of blood parameters; 4) studies comparing patients with recurrent AF (re-occurrence of AF in patients with history of treatment with anti-arrhythmic or electrophysiological interventions for AF) with those with non-recurrent AF focusing on blood parameters. Manuscripts that did not undergo peer-review, abstracts from congress presentations only, and gray literature were not included.

Primary and secondary blood parameters
--------------------------------------

Platelet count, MPV, PDW, WBC count, NLR, RBC count, and RDW were considered primary blood parameters. MCV, MCHC, HCT, and Hb were defined as secondary parameters.

Data extraction and outcome measures
------------------------------------

Six investigators (S.A-H-S, A.S, S.Y, T.L, M-P. S, and J-S. J) independently extracted the data. Discrepancies were resolved by a consensus standardized abstraction checklist used for recording data in each included study. Disagreements were discussed and resolved by senior authors (A.W, A.F-P, G.B.Z, G.D.S and H.C). The following items were extracted from the included studies: author name; publication year; country; study design; sample size; mean age; gender; coexistent cardiovascular diseases, and risk factors, such as diabetes mellitus, hypertension, and history of myocardial infarction; percentage of used anticoagulants; AF type; and details of blood parameters. In order to examine heterogeneity among trials, subgroup analyses of disparities in patients' characteristics were carried out for: (1) the era of publication (pre-2000 *vs.* post-2000); (2) geographical area (Asia, Europe, Africa, North-America, South-America, and Oceania); (3) study design (case-control *vs.* cohort); (4) sample size of studies (≤300 *vs.* \>300); (5) mean age (≤60 *vs.* \>60 years); (6) percentage of male patients (≤70% *vs.* \>70%); (7) presence of diabetes (≤30% *vs.* \>30%); (8) presence of hypertension (≤70% *vs.* \>70%); (9) cigarette smoking (≤30% *vs.* \>30%); (10) presence of myocardial infarction (≤20% *vs.* \>20%); (11) use of cardiovascular drugs, such as diuretics, angiotensin converting enzyme inhibitors, statins and beta-blockers (for each: ≤70% *vs.* \>70%); (12) AF-classification (chronic *vs.* non-chronic); (13) type of AF (paroxysmal, persistent, permanent); and (12) anticoagulation (code-1: not receiving anticoagulants in both groups; code-2: all participants receiving anticoagulants in both groups; code-3: range of percentages between both groups \>50%; code-4: range of percentages between both groups \<50%; code-5: no information available about anticoagulation in both groups; and code-6: anticoagulation information not available for 1 group only).

Homogenization of extracted data
--------------------------------

Continuous data are expressed as mean ± standard deviation (SD). For studies reporting interquartile ranges, the mean was estimated according to the formula \[minimum+maximum+2(median)\]/4 and SD was calculated based on the formula (maximum--minimum)/4 for groups with sample sizes of n ≤70 and (maximum--minimum)/6 for sample sizes of \>70 \[[@b6-medscimonitbasicres-23-179]\].

Quality assessment and statistical analysis
-------------------------------------------

The Newcastle-Ottawa scale was independently used by 3 investigators (S.A-H-S, M.G, and L.M) to assess the quality of studies \[[@b7-medscimonitbasicres-23-179]\]. Total scores ranged from 0 (worst quality) to 9 (best quality) for case-control or cohort studies. Data were analyzed by STATA 11.0 using METAN and METABIAS modules. For non-categorical data, pooled effect size measured was the weighted mean difference (WMD) with 95% CI. *P* value of \<0.1 for Q test or I^2^ \>50% showed significant heterogeneity among the studies. Heterogeneity among trials was examined by applying a random-effects model when indicated. Publication bias was assessed using the Begg tests. *P* value of \<0.05 was considered statistically significant.

Results
=======

Literature search strategy and included studies
-----------------------------------------------

Overall, 2150 studies were retrieved from the literature search and screened databases. We excluded 1179 studies (63.55%) after detailed evaluation during the first review due to unnecessary information (n=750), inadequate report of endpoints of interest (*n*=370), or report of non-matched data based on mean ±SD or median \[minimum--maximum\] (*n*=59). In total, 971 potentially relevant full-text articles were screened, with 70 studies being analyzed in the meta-analysis on new-onset AF and 23 studies on recurrent AF ([Supplementary Table 1](#s1-medscimonitbasicres-23-179){ref-type="supplementary-material"}) \[[@b8-medscimonitbasicres-23-179]--[@b77-medscimonitbasicres-23-179]\].

Association of hematologic parameters with new-onset AF
-------------------------------------------------------

### Platelet count

A total of 6468 cases were selected from 48 studies, of which 3098 were allocated to the AF group and 3370 to the SR group. Mean platelet count was 236.9×10^9^/L in the AF group and 239.9×10^9^/L in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Using a random-effects model, pooled analysis revealed that the mean platelet count was considerably lower in patients with AF than in patients with SR, with a WMD of −26.39×10^9^/L (95% CI: −27.80 to −24.99; p\<0.001, [Figure 1](#f1-medscimonitbasicres-23-179){ref-type="fig"}). Significant heterogeneity was observed among the studies (I^2^=92.9%; heterogeneity p\<0.001).

### MPV

A total of 4014 cases were included from 23 studies, of which 1838 were allocated to the AF group and 2176 to the SR group. The mean level of MPV was 9.18 FL in the AF group and 8.48 FL in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Pooled analysis revealed that MPV level was significantly higher in patients with AF compared to those with SR, with a WMD of 0.42 FL (95% CI: 0.39 to 0.46; p\<0.001, [Figure 2](#f2-medscimonitbasicres-23-179){ref-type="fig"}) using a random-effects model. There was significant heterogeneity among the studies (I^2^=95.7%; heterogeneity p\<0.001).

### PDW

A total of 553 cases were included from 3 studies, of which 275 and 278 were allocated to the AF group and the SR group, respectively. The mean level of PDW was 15.73% in the AF group and 15.60% in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Using a random-effects model, pooled analysis indicated that PDW was statistically lower in the AF group than in the SR group, with a WMD of −0.24% (95% CI: −0.39 to −0.09; p=0.001). There was significant heterogeneity among the studies (I^2^=88.5%; heterogeneity p\<0.001)

### WBC

A total of 7042 patients were included from 42 studies, of which 3105 were allocated to the AF group and 3937 to the SR group. The mean WBC count was 7.49×10^9^/L in patients with AF and 7.16×10^9^/L in those with SR (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Pooled analysis indicated that the mean count of WBC was similar in AF patients and those with SR, with a WMD of −0.005×10^9^/L (95% CI: −0.052 to 0.042; p=0.83, [Figure 3](#f3-medscimonitbasicres-23-179){ref-type="fig"}), with considerable heterogeneity among the studies (I^2^=87.2%; heterogeneity p\<0.001).

### NLR

A total of 1899 cases were selected from 10 studies, of which 677 were allocated to the AF group and 1222 to the SR group. The mean NLR was 3.56 in the AF group and 2.61 in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Pooled analysis showed that the NLR was remarkably higher in patients with AF compared to controls, with a WMD of 0.89 (95% CI: 0.79 to 0.99; p\<0.001, [Figure 4](#f4-medscimonitbasicres-23-179){ref-type="fig"}) using a random-effects model. There was significant heterogeneity among the studies (I^2^=93.6%; heterogeneity p\<0.001).

### RBC count

A total of 572 cases were included from 2 studies, of which 251 were allocated to the AF group and 321 to the SR group. The mean RBC count was 4.52×10^12^/L in the AF group and 4.39×10^12^/L in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Using a random-effects model, pooled analysis showed that the mean count of RBC was statistically higher in the AF group compared to the SR group, with a WMD of 0.28×10^12^/L (95% CI: 0.23 to 0.33; p\<0.001). Significant heterogeneity was observed among the studies (I^2^=96.8%; heterogeneity p\<0.001).

### RDW

A total of 1631 cases were included from 8 studies, of which 577 were allocated to the AF group and 1054 to the SR group. The mean of RDW was 14.01% in the AF group and 13.28% in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Using a random-effects model, pooled analysis revealed that RDW was significantly higher in the AF group than in the SR group, with a WMD of 0.61% (95% CI: 0.56 to 0.66; p\<0.001, [Figure 5](#f5-medscimonitbasicres-23-179){ref-type="fig"}). There was significant heterogeneity among the studies (I^2^=94.7%; heterogeneity p\<0.001)

### Secondary hematological parameters

MCHC was reported in 1 study, which was not included in the meta-analysis. According to pooled assessment analysis, the level of MCV (number of studies=4, WMD of −0.14 FL, 95% CI: −0.51 to 0.23; p=0.46 and I^2^=34%; heterogeneity p=0.2) and Hb (number of studies=27, WMD of 0.04 g/dL, 95% CI: −0.02 to 0.10; p=0.23 and I^2^=91.1%; heterogeneity p\<0.001) were similar in both groups. Pooled analysis showed that HCT (number of studies=11, WMD of 1.79%, 95% CI: 1.43 to 2.15; p\<0.001 and I^2^=80.6%%; heterogeneity p\<0.001) was significantly higher in the AF group compared to the SR group.

Association of hematologic parameters with recurrent AF
-------------------------------------------------------

### Platelet count

A total of 696 cases were selected from 4 studies, of which 207 were allocated to recurrent AF group and 489 to the non-recurrent AF group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Pooled effects analysis showed that the mean platelet count did not differ between groups, with a WMD of −2.71×10^9^/L (95% CI: −12.75 to 7.34; p=0.59). Significant heterogeneity was observed among the studies (I^2^=69.4%; heterogeneity p=0.02).

### WBC

A total of 3716 patients were included from 22 studies, of which 1223 were allocated to the recurrent AF group and 2493 to the non-recurrent AF group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). The mean WBC count was 6.89×10^9^/L in patients with recurrent AF and 6.79×10^9^/L in those with non-recurrent AF. Pooled analysis revealed that the mean count of WBC was statistically higher in the recurrent group compared to the non-recurrent group, with a WMD of 0.20×10^9^/L (95% CI: 0.08 to 0.32; p=0.002, [Figure 6](#f6-medscimonitbasicres-23-179){ref-type="fig"}), with considerable heterogeneity among the studies (I^2^=54.7%; heterogeneity p=0.001).

### NLR

A total of 1620 cases were selected from 7 studies, of which 446 were allocated to the recurrent AF group and 1174 to the non-recurrent AF group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Pooled assessment analysis indicated that the NLR was significantly higher in patients suffering from recurrent AF compared to the non-recurrent group, with a WMD of 0.37 (95% CI: 0.24 to 0.50; p\<0.001, [Figure 7](#f7-medscimonitbasicres-23-179){ref-type="fig"}). There was significant heterogeneity among the studies (I^2^=83.2%; heterogeneity p\<0.001).

### RDW

A total of 1209 cases were included from 5 studies, of which 423 were allocated to the recurrent AF group and 786 to the non-recurrent AF group (details in [Tables 1](#t1-medscimonitbasicres-23-179){ref-type="table"} and [2](#t2-medscimonitbasicres-23-179){ref-type="table"}). Using a random-effects model, pooled analysis revealed that RDW was considerably higher in the recurrent AF group than in the non-recurrent group, with a WMD of 0.28% (95% CI: 0.18 to 0.38; p\<0.001, [Figure 8](#f8-medscimonitbasicres-23-179){ref-type="fig"}). There was significant heterogeneity among the studies (I^2^=87.5%; heterogeneity p\<0.001).

### Secondary hematological parameters

MCV and Hb were investigated in at least 2 studies, which were included in the meta-analysis. According to pooled assessment analysis, the levels of MCV (number of studies=2, WMD of 0.21, 95% CI: −0.43 to 0.85; p=0.52 and I^2^=1.6%; heterogeneity p=0.31) and Hb (number of studies=9, WMD of 0.04 g/dL, 95% CI: −0.12 to −0.19; p=0.64 and I^2^=13.6%; heterogeneity p=0.32) were similar in both groups.

### Other parameters

There was an insufficient number of studies for analysis on association between MPV, RBC count, and HCT and recurrent AF.

### Publication bias and subgroup analysis

Begg tests suggested that all of the analyses were without publication bias except for association between Hb and recurrent AF. Extra details of characteristics of each study for exploration of heterogeneity factors are presented in [Supplementary Table 2](#s2-medscimonitbasicres-23-179){ref-type="supplementary-material"}. Details of subgroup analysis are reported in detail in [Supplementary Table 3](#s3-medscimonitbasicres-23-179){ref-type="supplementary-material"}.

Discussion
==========

AF is one of the most common cardiac arrhythmias in developing and developed countries, precipitating morbidities and mortalities \[[@b78-medscimonitbasicres-23-179],[@b79-medscimonitbasicres-23-179]\]. Various mechanisms are involved in AF, such as inflammation, oxidative stress, and prothrombotic state \[[@b79-medscimonitbasicres-23-179],[@b80-medscimonitbasicres-23-179]\]. Therefore, the complications of this arrhythmia and their negative effects on quality of life can be decreased by more accurate recognition of mechanisms, timely diagnosis, and appropriate treatment. Although taking patient history, considering the history of cardiac arrhythmia, clinical examinations, ECG, and Holter monitoring can assist in diagnosis and control of AF, some routine diagnostic actions which are performed daily in clinical practice might be of higher value than previously thought \[[@b81-medscimonitbasicres-23-179]\]. CBC is a routine lab test for most patients, particularly those with cardiovascular diseases hospitalized in cardiology and cardiac surgery wards, as well as CCUs or ICUs \[[@b81-medscimonitbasicres-23-179]\]. Hematological parameters in CBC tests can indicate hemodynamic status and are appropriate predictors for clinical outcomes of these patients \[[@b81-medscimonitbasicres-23-179]\]. Varastehravan et al. reported that hematological parameters had considerable ability in prognosis of ST-segment resolution in patients with ST-segment elevation myocardial infarction receiving streptokinase therapy \[[@b5-medscimonitbasicres-23-179]\].

In the present study, we investigated the association of hematological parameters with new-onset and recurrent AF in order to understand which hematological parameters could be reliable predictors of each type of AF. Although the majority of physicians and researchers have believed that platelet count in cases with new-onset AF is higher than in patients with SR, our findings revealed that the number of platelets was significantly lower in cases with new-onset AF compared to those with SR, resulting in the likelihood of lower platelet count to predict new-onset AF.

Our subgroup analysis showed an inverse relationship between platelet count and new-onset AF in cases of persistent AF, but this relationship was not found in cases of paroxysmal and permanent AF. On the other hand, there was no significant relationship between platelet count and new-onset AF in patients with chronic AF. According to our findings, sample size of the studies, age, diabetes mellitus, differences regarding treatment with anticoagulants, and type of AF are factors of heterogeneity. The present study found no remarkable relationship between platelet count and recurrent AF; therefore, platelet count could be a potential predictor for new-onset AF, but it does not appear to be a significant factor associated with recurrent AF. Regarding the results of this study, PDW was considerably lower in cases with new-onset AF compared to those with SR. Thus, PDW and platelet count both had an inverse relationship with the new-onset AF.

MPV is known as an important biomarker of platelet activity. Large platelets secrete many critical mediators of coagulation, inflammation, thrombosis, and atherosclerosis. Evidence shows a close relationship between MPV and cardiovascular risk factors, such as diabetes mellitus, hypertension, and hypercholesterolemia \[[@b82-medscimonitbasicres-23-179],[@b83-medscimonitbasicres-23-179]\]. Interestingly, in a recent study, Sansanayudh et al. reported an association between MPV and coronary artery disease (CAD). Patients with CAD and slow coronary blood flow had larger MPV than in the control group. They concluded that MPV might be used for risk stratification or to raise diagnostic accuracy of the traditional risk stratification markers in CAD patients \[[@b84-medscimonitbasicres-23-179]\].

The results of our study showed that MPV was also considerably higher in cases with new-onset AF compared to those with SR. According to our subgroup analysis, there was also a direct relationship between MPV and new-onset AF in both chronic and non-chronic AF. Sample sizes of the studies, differences in treatment with anticoagulants, and type of AF appeared to be factors of heterogeneity. Owing to insufficient number of studies on the association between PDW and MPV with recurrent AF, no analysis was performed in this regard.

There is a known relationship between inflammation and development of AF. Activities in hematopoietic tissues producing inflammatory leukocytes are closely associated with systemic inflammation, arterial inflammation, and cardiovascular events; however, their association with AF is unclear \[[@b85-medscimonitbasicres-23-179]\].

The findings of this study demonstrated that WBC count was not significantly different between cases of new-onset AF compared to those of SR; therefore, WBC is not proposed as a reliable predictor. The present study also confirmed that WBC count was not associated with new-onset AF for chronic and non-chronic AF. Our subgroup analysis indicated that risk factors such as diabetes mellitus, hypertension, and cigarette smoking could be factors of heterogeneity. On the other hand, our results revealed that WBC count was statistically higher in cases of recurrent AF compared to those with non-recurrent AF. Consequently, it can be stated that WBC count might be considered a predictor for recurrent AF, but not for new-onset AF. It also implies that possible inflammatory mechanisms are more active in patients who develop recurrent AF despite anti-arrhythmic therapy for AF. As a result, considering inflammatory markers as a valuable tool to detect the risk of recurrent AF after pharmacological interventions and electrophysiology could greatly help in terms of timely diagnosis of AF recurrence.

The neutrophil to lymphocyte ratio is a new systemic inflammatory marker and a prognostic indicator of cardiovascular diseases \[[@b86-medscimonitbasicres-23-179],[@b87-medscimonitbasicres-23-179]\]. The results of this study show that NLR is directly associated with new-onset and recurrent AF and generally could be an appropriate and efficient predictor for this disease. In our subgroup analysis, NLR also had this predictive ability for paroxysmal and persistent AF, while the association of NLR with permanent and chronic AF could not be detected due to the lack of relevant studies.

RDW is a parameter used to measure variability in the size of circulatory red blood cells obtained in CBC tests. Higher RDW reflects the presence of anisocytosis, which is associated with impaired erythropoiesis and RBC degradation appearing as chronic inflammation and a high level of oxidative stress \[[@b88-medscimonitbasicres-23-179]\].

Several studies suggested that RDW can predict poor outcomes in patients with heart failure, stable CAD, and acute myocardial infarction \[[@b89-medscimonitbasicres-23-179]--[@b91-medscimonitbasicres-23-179]\]. Similarly, our study showed that RDW was clearly higher in cases with new-onset AF compared to cases with SR. However, RDW was significantly increased in patients with recurrent AF versus non-recurrent AF, providing strong evidence that RDW can predicting both new-onset and recurrent AF. Only 2 studies investigated RBC count and its impact on AF, in which pooled analysis showed that RBC count was statistically higher in the AF group than in the SR group. No study was found investigating the relationship between this hematological parameter and recurrent AF.

Anemia increases the risk of cardiovascular complications, such as thromboembolic events, bleeding, and mortality in anticoagulated patients with AF. Patients with anemia and AF are supposed to be closely monitored while under treatment with all types of anticoagulants \[[@b92-medscimonitbasicres-23-179]\]. In the present study, Hb, HCT, MCV, and MCHC were examined as secondary hematological parameters. Pooled analysis found no significant differences in Hb levels comparing cases of new-onset AF with cases of SR. Notably, our subgroup analysis showed that the status of treatment with anticoagulants was not defined in a significant number of studies. Therefore, we had no information on whether patients enrolled in these studies had been receiving anticoagulant therapy. Concerning general findings, it appears that Hb is not a potential predictor for new-onset AF; however, this might change in the future by defining the therapeutic strategies with anticoagulants as well as the number of patients under treatment. On the other hand, there was an interesting finding about the type of AF. When the studies were sorted in terms of chronic and non-chronic AF, the level of Hb was considerably higher in non-chronic AF and significantly lower in chronic AF. This finding suggests that the type of AF in terms of acute or chronic pattern might have different effects on Hb changes. The merged results rejected any relationship between Hb and new-onset AF; however, based on our subgroup analysis, we believe that after categorizing the types of AF into chronic and non-chronic, Hb might be a predictor. The results also indicated that the level of Hb was similar in patients with recurrent AF and those with non-chronic AF. Performing subgroup analysis, we found that the lack of association of Hb changes with recurrent AF was not influenced by any factor. Therefore, we strongly corroborate the lack of association between this hematological parameter and recurrent AF.

MCV is a measure of the average red blood cell. Based on our results, the level of MCV did not significantly differ between cases of new-onset AF versus SR cases, thus MCV could not be suggested as a predictor for new-onset AF. Also, our subgroup analysis strongly supported this finding.

Only 2 studies investigated the association of MCV and recurrent AF, and the merged analysis showed that the level of MCV was not significantly related to new-onset AF. HCT is a test for measuring the volume of RBC in relation to the total volume of blood. In the present study, the percentage of HCT was notably higher in cases of new-onset AF versus SR cases. Our subgroup analysis revealed that HCT can predict new-onset AF in non-chronic AF, but this ability was not seen in chronic AF. Due to the insufficient number of studies, we were unable to evaluate the relationship between HCT and recurrent AF.

Lip et al. reported that anticoagulants can reduce the level of hemostatic and hematologic factors in AF patients and, consequently, differences in treatment strategies with anticoagulants in various studies could be considered as a factor of heterogeneity \[[@b93-medscimonitbasicres-23-179]--[@b95-medscimonitbasicres-23-179]\]. Our subgroup analysis of platelet count, RDW, MCV, HCT, and WBC indicated that differences in using anticoagulants could play a considerable role in the existence of heterogeneity.

It should also be noted that in the meta-analysis on non-experimental studies, more heterogeneity was found, which can be explained by the following: 1) less controlled biases; 2) more confounding factors; and 3) differences in defining outcomes. Millions of CBC tests are performed daily for a large number of hospitalized patients with cardiovascular diseases throughout the world. In the present study, we found that CBC tests, apart from their ability to show a number of various pathologies already well known in clinical practice, might also play a significant role in diagnosis of various types of cardiac arrhythmias. Therefore, in addition to taking patient history, ECG, and Holter monitoring, the information from CBC in terms of AF should also be taken into account as an important diagnostic parameter. Therefore, we should be aware that, despite being one the most routine laboratory tests, the usefulness of CBC should not be underestimated.

Conclusions
===========

Indeed, according to the results of previous research on potential predictive role of various CBC tests on the occurrence of AF that were conglomerated in our meta-analysis, CBC tests are a relatively easy to use and inexpensive tool to provide additional information on potential AF. Although CBC testing cannot replace standard diagnostics, they may be a valuable method to get some additional information in clinical diagnostics. In general, considering the results of this study, we conclude that lower platelet count and PDW, as well as higher MPV, NLR, RBC, RDW, and HTC, could be associated with new-onset AF. We strongly emphasize that MPV, NLR, and RDW have better predictive value in clinical practice for AF. Patients with AF who are under treatment are at high risk of recurrent AF; as a result, CBC is of particular importance for these patients. Our results also indicated that WBC, NLR, and PDW are hematological parameters with significant ability to predict recurrent AF. Therefore, emphasizing the potential predictive role of hematological parameters for new-onset and recurrent AF, we strongly recommend adding CBC testing to the diagnostic modalities of AF in clinical practice.

Supplementary Tables
====================

###### 

Included, and excluded studies according to primary hematological parameters.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical outcomes and biomarkers    Studies were identified and screened \[n\]   Studies were excluded according to title, abstract or full text (Secondary exclude) \[n\]   Studies were included \[n\]                                                        Data for occurrence and recurrence \[n\]
  ----------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------
  Platelet count                      292                                          254                                                                                         38 approved articles with totally 52 enrolled data for meta-analysis (48 studies   **Occurrence:** 48\
                                                                                                                                                                                                                                                                  **Recurrence:** 4

  Mean platelet volume                147                                          129                                                                                         18 approved articles with totally 24 enrolled data for meta-analysis               **Occurrence:** 23\
                                                                                                                                                                                                                                                                  **Recurrence:** 1

  Platelet distribution width         11                                           9                                                                                           2 approved articles with totally 3 enrolled data for meta-analysis                 **Occurrence:** 3\
                                                                                                                                                                                                                                                                  **Recurrence:** 0

  White blood cell                    348                                          299                                                                                         49 approved articles with totally 64 enrolled data for meta-analysis               **Occurrence:** 42\
                                                                                                                                                                                                                                                                  **Recurrence:** 22

  Neutrophil to lymphocyte ratio      41                                           26                                                                                          15 approved articles with totally 17 enrolled data for meta-analysis               **Occurrence:** 10\
                                                                                                                                                                                                                                                                  **Recurrence:** 7

  Red blood cell                      83                                           81                                                                                          2 approved articles with totally 2 enrolled data for meta-analysis                 **Occurrence:** 2\
                                                                                                                                                                                                                                                                  **Recurrence:** 0

  Red blood cell distribution width   49                                           38                                                                                          11 approved articles with totally 13 enrolled data for meta-analysis               **Occurrence:** 8\
                                                                                                                                                                                                                                                                  **Recurrence:** 5
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Extra details of characteristics of each study for exploration of heterogeneity factors.

  First Author                                                                   Geographic Area   Total N   Total age   Total male   Total DM   Total HTN   Total CS   Total Diuretic   Total ACEI   Total. Statin   Total BB   AC-code   Chronic or not
  ------------------------------------------------------------------------------ ----------------- --------- ----------- ------------ ---------- ----------- ---------- ---------------- ------------ --------------- ---------- --------- ----------------
  **Occurrence of AF**                                                                                                                                                                                                                     
  Balci (Male subjects) \[[@b8-medscimonitbasicres-23-179]\]                     European          35        ND          100          ND         ND          ND         ND               ND           ND              ND         5         ND
  Balci (Female subjects) \[[@b8-medscimonitbasicres-23-179]\]                   European          153       ND          0            ND         ND          ND         ND               ND           ND              ND         5         ND
  Gurses \[[@b9-medscimonitbasicres-23-179]\]                                    European          172       56.5        52.35        13.95      51.75       ND         ND               ND           ND              ND         5         Non-chronic
  Karatas \[[@b10-medscimonitbasicres-23-179]\]                                  European          621       61.05       72.5         23         45.5        64         ND               ND           0               ND         2         Non-chronic
  Korantzopoulos \[[@b11-medscimonitbasicres-23-179]\]                           European          101       76.5        46.5         27.5       88.5        ND         ND               ND           ND              ND         3         Non-chronic
  Akdag \[[@b12-medscimonitbasicres-23-179]\]                                    European          148       64.05       60           16.5       22          23.5       ND               ND           ND              ND         6         Combined types
  Akyuz \[[@b13-medscimonitbasicres-23-179]\]                                    European          90        62.25       72.25        29         42.5        34.25      14.5             20.75        32.5            23         4         Combined types
  Chavaria \[[@b14-medscimonitbasicres-23-179]\]                                 North America     290       65.65       74.5         29.05      65.65       55.05      ND               ND           ND              ND         5         ND
  Drabik (Persistent AF) \[[@b15-medscimonitbasicres-23-179]\]                   European          97        60.1        64.975       20         48.85       22.85      ND               52.25        53.15           60.6       4         Non-chronic
  Drabik (Paroxysmal AF) \[[@b15-medscimonitbasicres-23-179]\]                   European          91        60          55.15        16.4       46.05       20         ND               54.05        47.45           57.25      4         Non-chronic
  Acet (Paroxysmal AF) \[[@b16-medscimonitbasicres-23-179]\]                     European          134       62.05       44           16.5       18          21.5       ND               ND           ND              ND         5         Non-chronic
  Acet (Persistent and permanent AF) \[[@b16-medscimonitbasicres-23-179]\]       European          126       62.85       43.5         21.5       24          28.5       ND               ND           ND              ND         5         Combined types
  Arik (effective INR) \[[@b17-medscimonitbasicres-23-179]\]                     European          248       69.65       40.7         6.05       68.95       13.7       27               59.25        ND              59.7       5         chronic
  Arik (ineffective INR) \[[@b17-medscimonitbasicres-23-179]\]                   European          248       69.45       37.9         6.85       65.35       12.1       24.2             55.65        ND              61.3       5         chronic
  Distelmaier \[[@b18-medscimonitbasicres-23-179]\]                              North America     198       73.5        61           24         60.5        ND         ND               ND           ND              ND         5         Non-chronic
  Erdogan (with normal ventricular rate) \[[@b19-medscimonitbasicres-23-179]\]   European          67        69.55       49.28        10         65          6          17               53.5         10              43.3       3         chronic
  Erdogan (with high ventricular rate) \[[@b19-medscimonitbasicres-23-179]\]     European          63        68.8        49.055       13.3       56.5        8          25               52           3.5             43.3       3         chronic
  Zheng \[[@b20-medscimonitbasicres-23-179]\]                                    Asian             217       61.735      58.63        10.84      49.275      32.74      ND               ND           ND              ND         5         ND
  Xu (without thrombotic events) \[[@b21-medscimonitbasicres-23-179]\]           Asian             115       66.095      50.45        37.4       53.1        38.25      ND               42.6         29.55           43.55      4         chronic
  Xu (with thrombotic events) \[[@b21-medscimonitbasicres-23-179]\]              Asian             115       67.975      51.3         36.5       57.5        31.25      ND               40.8         26.05           40.95      4         chronic
  Gungor \[[@b22-medscimonitbasicres-23-179]\]                                   European          177       47.2        57.8         3.35       14.75       23.15      ND               ND           ND              10.6       3         ND
  Liu \[[@b23-medscimonitbasicres-23-179]\]                                      Asian             234       ND          ND           ND         ND          ND         ND               ND           ND              ND         5         Non-chronic
  Sarikaya \[[@b24-medscimonitbasicres-23-179]\]                                 European          126       71.03       50           38         100         ND         ND               ND           ND              ND         5         ND
  Sonmez \[[@b25-medscimonitbasicres-23-179]\]                                   European          85        70          37           24.21      63.255      ND         14.16            47.17        15.41           35.6       4         Non-chronic
  Ulu \[[@b26-medscimonitbasicres-23-179]\]                                      European          57        ND          ND           0          0           ND         ND               ND           ND              ND         5         ND
  Berge \[[@b27-medscimonitbasicres-23-179]\]                                    European          189       75          71.025       8          48          ND         19               21           34.5            28         4         Combined types
  Ertas (without stroke) \[[@b28-medscimonitbasicres-23-179]\]                   European          111       53.5        51           8.5        32.5        2          ND               17           ND              30         3         ND
  Ertas (with stroke) \[[@b28-medscimonitbasicres-23-179]\]                      European          63        54.5        47           10         47          5          ND               24           ND              16.5       3         ND
  Gungor \[[@b29-medscimonitbasicres-23-179]\]                                   European          140       42.55       66.4         0          0           31         ND               ND           ND              ND         5         ND
  Turgut \[[@b30-medscimonitbasicres-23-179]\]                                   European          162       63          52           100        65.5        41.5       6.5              23.5         18              16.5       4         chronic
  Jaremo (healthy control) \[[@b31-medscimonitbasicres-23-179]\]                 European          82        67.5        66.73        5.17       21.55       2.585      18.9             13.79        14.655          41.3       4         ND
  Jaremo (disease control) \[[@b31-medscimonitbasicres-23-179]\]                 European          130       71.5        68.1         12.75      43.75       9.485      28.65            26.25        25.05           55.92      4         ND
  Sahin \[[@b32-medscimonitbasicres-23-179]\]                                    European          144       64.865      49.75        100        66.5        44.5       ND               ND           ND              ND         5         Non-chronic
  Tekin \[[@b33-medscimonitbasicres-23-179]\]                                    European          219       73.5        35.5         13.5       68.5        19         ND               ND           ND              ND         5         chronic
  Turfan (without stroke) \[[@b34-medscimonitbasicres-23-179]\]                  European          135       59.5        54.55        15.6       33.1        55.5       ND               ND           ND              ND         4         ND
  Turfan (with stroke) \[[@b34-medscimonitbasicres-23-179]\]                     European          121       62.5        52.05        24.6       27          50.6       ND               ND           ND              ND         4         ND
  Feng \[[@b35-medscimonitbasicres-23-179]\]                                     Asian             374       65.8        61.75        17.65      53.2        25.65      23               41.95        44.85           42.5       4         ND
  Liu (Paroxysmal AF) \[[@b36-medscimonitbasicres-23-179]\]                      Asian             101       64.35       62.5         5          32.5        ND         ND               21           15              34         3         Non-chronic
  Liu (Persistent AF) \[[@b36-medscimonitbasicres-23-179]\]                      Asian             107       65.8        61           6.5        35          ND         ND               29           13.5            35         3         Non-chronic
  Yoshizaki \[[@b37-medscimonitbasicres-23-179]\]                                Asian             176       70          76           32         65          52.5       ND               37.55        38.85           10.6       5         Non-chronic
  Hayashi (Paroxysmal AF) \[[@b38-medscimonitbasicres-23-179]\]                  Asian             27        57.95       92.5         14.5       48.5        ND         ND               40.5         26              ND         2         Non-chronic
  Hayashi (Chronic AF) \[[@b38-medscimonitbasicres-23-179]\]                     Asian             27        61.45       92.5         11.05      52          ND         ND               37           26              ND         2         chronic
  Fu \[[@b39-medscimonitbasicres-23-179]\]                                       Asian             169       54.45       63.5         ND         ND          42.45      ND               ND           12.9            6.1        4         Combined types
  Liu \[[@b40-medscimonitbasicres-23-179]\]                                      Asian             451       58.35       51.435       ND         100         23.7       14.85            71.55        61.15           42.7       5         Combined types
  Letsas (Paroxysmal AF) \[[@b41-medscimonitbasicres-23-179]\]                   European          93        64.35       59           6          60.5        ND         ND               43           15.5            34         5         Non-chronic
  Letsas (Permanent AF) \[[@b41-medscimonitbasicres-23-179]\]                    European          89        66.6        59.5         11         63          ND         ND               52.5         13.5            35.5       5         chronic
  Luan (Persistent AF) \[[@b42-medscimonitbasicres-23-179]\]                     Asian             53        53.25       50.855       0          26.21       30.2       ND               ND           ND              ND         5         Non-chronic
  Luan (Paroxysmal AF) \[[@b42-medscimonitbasicres-23-179]\]                     Asian             55        50.99       52.385       0          24.93       30.9       ND               ND           ND              ND         5         Non-chronic
  Alberti \[[@b43-medscimonitbasicres-23-179]\]                                  European          51        64.45       47.05        ND         ND          ND         ND               ND           ND              ND         1         Non-chronic
  Dai \[[@b44-medscimonitbasicres-23-179]\]                                      Asian             522       53.065      74.7         6.1        17          ND         ND               ND           ND              ND         5         Non-chronic
  Ichiki \[[@b45-medscimonitbasicres-23-179]\]                                   Asian             72        51.5        80.205       16         37.5        ND         ND               8            15              ND         5         Non-chronic
  Yao (Persistent AF) \[[@b46-medscimonitbasicres-23-179]\]                      Asian             150       54.1        76.8         7.4        0           42.4       ND               ND           8.1             13.2       4         Non-chronic
  Yao (Paroxysmal AF) \[[@b46-medscimonitbasicres-23-179]\]                      Asian             339       53.35       74.95        4.25       0           46.55      ND               ND           6.6             7.85       4         Non-chronic
  Colkesen \[[@b47-medscimonitbasicres-23-179]\]                                 European          190       54          38           18.5       41.5        ND         ND               ND           28              ND         4         Non-chronic
  Choudhury (disease control) \[[@b48-medscimonitbasicres-23-179]\]              European          192       63.31       74           10.5       66.4        ND         33.15            55.7         46.5            43.7       4         ND
  Choudhury (healthy control) \[[@b48-medscimonitbasicres-23-179]\]              European          177       62.305      72           4.1        31.8        ND         17.75            26.85        14.45           21.9       4         ND
  Pirat \[[@b49-medscimonitbasicres-23-179]\]                                    European          39        49.5        51.5         8          26.5        32         ND               24.5         ND              38         5         Non-chronic
  Yip \[[@b50-medscimonitbasicres-23-179]\]                                      Asian             82        65.75       63.05        9.7        34.7        5.65       ND               23.4         15.3            ND         3         chronic
  Kamath (Paroxysmal and persistent AF) \[[@b51-medscimonitbasicres-23-179]\]    European          62        63.5        51.6         ND         ND          ND         ND               ND           ND              ND         1         Non-chronic
  Kamath (Permanent AF) \[[@b51-medscimonitbasicres-23-179]\]                    European          124       66          52.65        ND         ND          ND         ND               ND           ND              ND         1         chronic
  Kamath (Paroxysmal AF) \[[@b52-medscimonitbasicres-23-179]\]                   European          58        63          48.27        6.85       24.135      5.17       ND               ND           ND              ND         4         Non-chronic
  Kamath (Permanent AF) \[[@b52-medscimonitbasicres-23-179]\]                    European          116       65          52.29        5.15       30.45       5.17       ND               ND           ND              ND         4         chronic
  Kamath \[[@b53-medscimonitbasicres-23-179]\]                                   European          143       70          54.18        5.375      29.565      ND         ND               ND           ND              ND         1         ND
  Kamath \[[@b54-medscimonitbasicres-23-179]\]                                   European          57        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         chronic
  Peverill \[[@b55-medscimonitbasicres-23-179]\]                                 Oceania           163       55          84.6         ND         ND          ND         ND               ND           ND              ND         5         ND
  Kahn (without stroke) \[[@b56-medscimonitbasicres-23-179]\]                    North America     81        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         chronic
  Kahn (with stroke) \[[@b56-medscimonitbasicres-23-179]\]                       North America     36        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         chronic
  Lip \[[@b57-medscimonitbasicres-23-179]\]                                      European          77        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         chronic
  Gustafsson (without stroke) \[[@b58-medscimonitbasicres-23-179]\]              European          40        77          ND           10         25          25         ND               ND           ND              ND         1         ND
  Gustafsson (with stroke) \[[@b58-medscimonitbasicres-23-179]\]                 European          40        77          ND           12.5       27.5        30         ND               ND           ND              ND         1         ND
  **Recurrence of AF**                                                                                                                                                                                                                     
  Gurses \[[@b9-medscimonitbasicres-23-179]\]                                    European          86        56.8        57.7         15.8       48.55       ND         ND               21.2         16.5            ND         5         Non-chronic
  Hongliang Li \[[@b59-medscimonitbasicres-23-179]\]                             Asian             104       62.5        43.9         24.45      46.1        37.45      ND               41           49.65           42.4       4         Non-chronic
  Yanagisawa (without heart failure) \[[@b60-medscimonitbasicres-23-179]\]       Asian             678       61.1        76           12.5       46          ND         3.5              35           ND              31.5       5         Non-chronic
  Yanagisawa (with heart failure) \[[@b60-medscimonitbasicres-23-179]\]          Asian             79        63.6        74.5         20         38          ND         77.5             58           ND              81.5       5         Non-chronic
  Aksu \[[@b61-medscimonitbasicres-23-179]\]                                     European          49        59.65       52.5         16.5       48.5        47         ND               ND           ND              ND         5         Non-chronic
  Gurses \[[@b62-medscimonitbasicres-23-179]\]                                   European          299       55.7        51.15        13.2       42.4        31         ND               ND           ND              ND         4         Non-chronic
  Karavelioglu \[[@b63-medscimonitbasicres-23-179]\]                             European          218       64.4        41.095       18         58.5        21         ND               23.5         10.5            67         5         Non-chronic
  Wen \[[@b64-medscimonitbasicres-23-179]\]                                      Asian             75        63.62       ND           7.5        57.5        20         ND               ND           30              ND         5         Non-chronic
  Guo Xueyuan \[[@b65-medscimonitbasicres-23-179]\]                              Asian             379       49.665      73.55        0          0           ND         ND               ND           ND              ND         5         ND
  Aribas \[[@b66-medscimonitbasicres-23-179]\]                                   European          149       60          ND           29         62.5        18.5       ND               ND           ND              ND         2         Non-chronic
  Bing Li \[[@b67-medscimonitbasicres-23-179]\]                                  Asian             288       57          71.1         28.65      55.05       38.15      ND               38           14.2            27.7       5         Non-chronic
  Canpolat \[[@b68-medscimonitbasicres-23-179]\]                                 European          251       55.2        54.85        15.15      44.35       36.55      ND               51.25        18.05           ND         5         Non-chronic
  Im \[[@b69-medscimonitbasicres-23-179]\]                                       Asian             499       56.4        73.65        15.55      43.9        ND         ND               ND           ND              ND         5         Non-chronic
  Xiao-nan HE \[[@b70-medscimonitbasicres-23-179]\]                              Asian             330       59.5        66.3         ND         48.65       ND         ND               50           14              52         5         Non-chronic
  Ferro \[[@b71-medscimonitbasicres-23-179]\]                                    European          144       70.95       56.5         14         87.5        5          ND               46.5         22.5            ND         2         Non-chronic
  Smit \[[@b72-medscimonitbasicres-23-179]\]                                     European          100       64          73.8         11.9       65.95       15         41.2             69.05        36.65           89.3       5         Non-chronic
  Wang (Paroxysmal AF) \[[@b73-medscimonitbasicres-23-179]\]                     Asian             103       57.5        34.8         ND         41.65       ND         ND               ND           ND              4.24       5         Non-chronic
  Wang (Persistent AF) \[[@b73-medscimonitbasicres-23-179]\]                     Asian             55        52.5        74.65        ND         50.35       ND         ND               ND           ND              5.65       5         Non-chronic
  Liu (Paroxysmal AF) \[[@b74-medscimonitbasicres-23-179]\]                      Asian             77        56          75.6         ND         37.3        ND         ND               ND           ND              ND         2         Non-chronic
  Liu (Persistent AF) \[[@b74-medscimonitbasicres-23-179]\]                      Asian             44        53.05       84.85        ND         51.2        ND         ND               ND           ND              ND         2         Non-chronic
  Vizzardi \[[@b75-medscimonitbasicres-23-179]\]                                 European          106       69          61           12.05      ND          ND         ND               8            ND              ND         5         Non-chronic
  Letsas \[[@b76-medscimonitbasicres-23-179]\]                                   European          72        54.55       81.5         21.5       21.5        ND         ND               23           14.5            ND         5         Non-chronic
  Korantzopoulos \[[@b77-medscimonitbasicres-23-179]\]                           European          30        68.5        48.39        7.1        64.25       4.75       30.95            35.7         5.55            ND         5         Non-chronic

###### 

Subgroup-analysis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroup                          Studies (N)                    WMD (95% CI)                I-squared and Heterogeneity-P-value and Effect-P-value respectively   Is this general item as heterogeneity factor?\
                                                                                                                                                                     1.Yes, probably\
                                                                                                                                                                     2. No
  --------------------------------- ------------------------------ --------------------------- --------------------------------------------------------------------- ------------------------------------------------
  **Occurrence of AF**                                                                                                                                               

                                                                                                                                                                     

  **Platelet count**                                                                                                                                                 

                                                                                                                                                                     

  **Year of Publication**                                                                                                                                            No

  \>2000                            43                             −23.75 (−25.22 to −22.29)   91% and 0.001 and 0.001                                               

  ≤2000                             5                              −56.50 (−61.45 to −51.55)   90.7% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                Yes, probably

  Asian                             7                              −3.88 (−10.98 to 3.22)      13.8% and 0.324 and 0.284                                             

  European                          36                             −29.41 (−30.95 to −27.88)   93.7% and 0.001 and 0.001                                             

  Africa                            --                             --                          --                                                                    

  North American                    4                              −12.11 (−16.25 to −7.96)    0.0% and 0.476 and 0.001                                              

  South American                    --                             --                          --                                                                    

  Australia                         1                              −23 (−40.50 to −5.49)       --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                No

  Cohort                            8                              −29.09 (−31.01 to −27.16)   92.4% and 0.001 and 0.001                                             

  Case-control                      40                             −23.30 (−25.36 to −21.25)   93% and 0.001 and 0.001                                               

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             2                              −6.33 (−19.68 to 7.03)      0.0% and 0.689 and 0.353                                              

  ≤300                              46                             −26.61 (−28.02 to −25.20)   93.1% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       No

  \>60 years                        35                             −27.69 (−29.13 to −26.25)   94% and 0.001 and 0.001                                               

  ≤60 years                         8                              −2.68 (−9.46 to 4.10)       78.4% and 0.001 and 0.438                                             

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             9                              −29.76 (−31.69 to −27.83)   83.8% and 0.001 and 0.001                                             

  ≤70%                              32                             −15.69 (−17.94 to −13.43)   90.5% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              Yes, probably

  \>30%                             3                              −0.27 (−9.57 to 9.01)       35.9% and 0.210 and 0.953                                             

  ≤30%                              35                             −24.77 (−26.27 to −23.26)   92.2% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              39                             −24.91 (−26.38 to −23.44)   92.5% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              No

  \>30%                             10                             −16.36 (−21.68 to −11.04)   92.8% and 0.001 and 0.001                                             

  ≤30%                              20                             −22.62 (−25.67 to −19.56)   92.4% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              13                             −28.39 (−30.26 to −26.52)   85.7% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              22                             −25.47 (−27.18 to −23.76)   86.5% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              21                             −25.33 (−27.06 to −23.61)   88% and 0.001 and 0.001                                               

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              21                             −25.36 (−27.06 to −23.66)   86.6% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    Yes, probably

  1                                 10                             −52.72 (−56.32 to −49.12)   92.3% and 0.001 and 0.001                                             

  2                                 3                              1.69 (−17.11 to 20.53)      67.3% and 0.047 and 0.860                                             

  3                                 6                              −10.36 (−21.43 to 0.69)     0.0% and 0.703 and 0.066                                              

  4                                 19                             −24.85 (−26.58 to −23.13)   91.6% and 0.001 and 0.001                                             

  5                                 9                              −11.38 (−14.88 to −7.88)    36.4% and 0.127 and 0.001                                             

  6                                 1                              17.40 (−6.03 to 40.83)      --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             Yes, probably

  Chronic                           16                             −2.80 (−7.77 to 2.16)       18.1% and 0.246 and 0.268                                             

  Non-chronic                       11                             −20.88 (−23.55 to −18.20)   95.7% and 0.001 and 0.001                                             

                                                                                                                                                                     

  Type of AF                                                                                                                                                         Yes, probably

  Paroxysmal                        5                              −3.72 (−9.24 to 1.79)       72.1% and 0.006 and 0.186                                             

  Persistent                        3                              −41.93 (−46.40 to −37.46)   97.4% and 0.001 and 0.001                                             

  Permanent                         6                              −5.09 (−11.96 to 1.78)      55.3% and 0.048 and 0.147                                             

                                                                                                                                                                     

  **Mean platelet volume**                                                                                                                                           

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                No

  Asian                             3                              1.37 (1.16 to 1.58)         95.9% and 0.001 and 0.001                                             

  European                          19                             0.39 (0.35 to 0.43)         95.2% and 0.001 and 0.001                                             

  Africa                            --                             --                          --                                                                    

  North American                    --                             --                          --                                                                    

  South American                    --                             --                          --                                                                    

  Australia                         1                              −0.20 (−0.63 to 0.23)       --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                No

  Cohort                            4                              1.37 (1.14 to 1.60)         94.7% and 0.001 and 0.001                                             

  Case-control                      19                             0.39 (0.35 to 0.43)         95.4% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Number of population**                                                                                                                                           Yes, probably

  \>300                             2                              0.90 (0.67 to 1.13)         0.0% and 0.666 and 0.001                                              

  ≤300                              21                             0.41 (0.36 to 0.45)         96% and 0.001 and 0.001                                               

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       No

  \>60 years                        16                             0.58 (0.54 to 0.63)         94.1and 0.001 and 0.001                                               

  ≤60 years                         4                              0.23 (0.05 to 0.42)         93.5% and 0.001 and 0.012                                             

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             6                              0.59 (0.46 to 0.71)         93.9% and 0.001 and 0.001                                             

  ≤70%                              16                             0.40 (0.36 to 0.44)         96.4% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              No

  \>30%                             4                              0.63 (0.57 to 0.69)         96.8% and 0.001 and 0.001                                             

  ≤30%                              16                             0.49 (0.42 to 0.57)         92.7% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              20                             0.58 (0.53 to 0.62)         93.8% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              No

  \>30%                             8                              0.68 (0.62 to 0.74)         94.7% and 0.001 and 0.001                                             

  ≤30%                              8                              0.37 (0.28 to 0.45)         92.1% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              9                              0.54 (0.49 to 0.59)         94.3% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              11                             0.57 (0.52 to 0.62)         95.8% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              11                             0.66 (0.60 to 0.71)         94.7% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              12                             0.55 (0.50 to 0.60)         95.8% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    Yes, probably

  1                                 --                             --                          --                                                                    

  2                                 1                              0.80 (0.26 to 1.33)         --                                                                    

  3                                 3                              0.081 (−0.109 to 0.272)     66.1% and 0.053 and 0.404                                             

  4                                 10                             0.67 (0.62 to 0.73)         95.1% and 0.001 and 0.001                                             

  5                                 8                              0.108 (0.046 to 0.17)       93.6% and 0.001 and 0.001                                             

  6                                 1                              1.10 (0.75 to 1.45)         --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             No

  Chronic                           8                              0.55 (0.49 to 0.60)         95.7% and 0.001 and 0.001                                             

  Non-chronic                       3                              0.85 (0.58 to 1.13)         88.6% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        1                              1.70 (1.20. to 2.19)        --                                                                    

  Persistent                        1                              0.32 (−0.09 to 0.73)        --                                                                    

  Permanent                         4                              0.28 (0.17 to 0.38)         91.7% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **WBC**                                                                                                                                                            

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                No

  Asian                             15                             0.001 (−0.058 to 0.06)      80.8% and 0.001 and 0.973                                             

  European                          25                             −0.05 (−0.13 to 0.023)      89.3% and 0.001 and 0.159                                             

  Africa                            --                             --                          --                                                                    

  North American                    2                              0.828 (0.46 to 1.187)       0.0% and 0.365 and 0.001                                              

  South American                    --                                                         --                                                                    

  Australia                         --                                                         --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                Yes, probably

  Cohort                            4                              0.370 (−0.083 to 0.823)     13.2% and 0.326 and 0.109                                             

  Case-control                      38                             −0.009 (−0.057 to 0.039)    88.2% and 0.001 and 0.708                                             

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             5                              0.035 (−0.047 to 0.117)     84.8% and 0.001 and 0.403                                             

  ≤300                              37                             −0.025 (−0.083 to 0.033)    87.7% and 0.001 and 0.398                                             

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       No

  \>60 years                        27                             −0.060 (−0.140 to 0.019)    88.3% and 0.001 and 0.136                                             

  ≤60 years                         15                             0.025 (−0.033 to 0.084)     85.2% and 0.001 and 0.397                                             

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             11                             0.009 (−0.051 to 0.070)     86.4% and 0.001 and 0.761                                             

  ≤70%                              31                             −0.027 (−0.102 to 0.048)    87.8% and 0.001 and 0.481                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              Yes, probably

  \>30%                             2                              0.216 (−0.419 to 0.852)     0.0% and 0.789 and 0.505                                              

  ≤30%                              38                             0.055 (0.005 to 0.104)      85% and 0.001 and 0.030                                               

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   Yes, probably

  \>70%                             2                              −0.743 (−0.952 to −0.535)   0.0% and 0.873 and 0.001                                              

  ≤70%                              39                             0.097 (0.046 to 0.147)      80.5% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              Yes, probably

  \>30%                             11                             0.053 (−0.010 to 0.115)     26.4% and 0.193 and 0.102                                             

  ≤30%                              16                             0.231 (0.123 to 0.339)      83.9% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              8                              0.061 (−0.102 to 0.224)     41.9% and 0.099 and 0.464                                             

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             1                              −0.70 (−1.269 to −0.131)    --                                                                    

  ≤70%                              21                             0.012 (−0.086 to 0.111)     83.2% and 0.001 and 0.804                                             

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              21                             −0.00 (−0.057 to 0.506)     81.8% and 0.001 and 0.990                                             

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              21                             0.071 (0.015 to 0.127)      76.2% and 0.001 and 0.012                                             

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    Yes, Probably

  1                                 1                              −0.70 (−0.875 to −0.525)    --                                                                    

  2                                 3                              0.661 (−0.627 to 1.949)     0.0% and 0.924 and 0.314                                              

  3                                 9                              −0.232 (−0.397 to −0.067)   85.4% and 0.001 and 0.006                                             

  4                                 8                              0.054 (−0.006 to 0.115)     87.6% and 0.001 and 0.077                                             

  5                                 20                             0.132 (0.030 to 0.233)      85% and 0.001 and 0.011                                               

  6                                 1                              0.400 (−0.220 to 1.020)     --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             Yes, probably

  Chronic                           8                              0.125 (−0.048 to 0.299)     0.0% and 0.833 and 0.156                                              

  Non-chronic                       22                             −0.050 (−0.102 to 0.001)    92% and 0.001 and 0.056                                               

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     Yes, probably

  Paroxysmal                        9                              −0.087 (−0.161 to −0.014)   88.6% and 0.001 and 0.020                                             

  Persistent                        6                              −0.019 (−0.101 to 0.062)    95.2% and 0.001 and 0.641                                             

  Permanent                         5                              0.069 (−0.120 to 0.259)     0.0% and 0.958 and 0.473                                              

                                                                                                                                                                     

  **NLR**                                                                                                                                                            

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                No

  Asian                             --                             --                          --                                                                    

  European                          9                              0.901 (0.802 to 1.000)      94% and 0.001 and 0.001                                               

  Africa                            --                             --                          --                                                                    

  North American                    1                              −0.640 (−1.711 to 0.431)    --                                                                    

  South American                    --                                                         --                                                                    

  Australia                         --                                                         --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                No

  Cohort                            1                              −0.640 (−1.711 to 0.431)    --                                                                    

  Case-control                      9                              0.901 (0.802 to 1.000)      94% and 0.001 and 0.001                                               

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             1                              1.200 (−0.789 to 3.189)     --                                                                    

  ≤300                              9                              0.887 (0.789 to 0.986)      94.3% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       No

  \>60 years                        7                              1.030 (0.919 to 1.141)      91.5% and 0.001 and 0.001                                             

  ≤60 years                         3                              0.365 (0.152 to 0.579)      95.1% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Male**                                                                                                                                                           Yes, probably

  \>70%                             2                              −0.277 (−1.170 to 0.716)    60.8% and 0.110 and 0.637                                             

  ≤70%                              8                              0.901 (0.801 to 1.00)       94.7% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              No

  \>30%                             1                              0.670 (0.201 to 1.139)      --                                                                    

  ≤30%                              9                              0.898 (0.797 to 0.999)      94.3% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   

  \>70%                             All of studies: ≤70%                                                                                                             

  ≤70%                                                                                                                                                               

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              No

  \>30%                             3                              0.492 (0.072 to 0.912)      62.5% and 0.069 and 0.022                                             

  ≤30%                              6                              0.928 (0.824 to 1.032)      96.2% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              1                              0.600 (0.146 to 1.054)      --                                                                    

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              3                              1.025 (0.687 to 1.364)      91.2% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              2                              0.630 (0.187 to 1.072)      0.0% and 0.564 and 0.005                                              

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              4                              0.408 (0.215 to 0.601)      92.8% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    No

  1                                 --                             --                          --                                                                    

  2                                 1                              1.200 (−0.789 to 3.189)     --                                                                    

  3                                 3                              0.365 (0.152 to 0.579)      95.1% and 0.001 and 0.001                                             

  4                                 1                              0.600 (0.146 to 1.054)      --                                                                    

  5                                 4                              1.081 (0.962 to 1.199)      95.4% and 0.001 and 0.001                                             

  6                                 1                              0.700 (0.236 to 1.164)      --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             No

  Chronic                           --                             --                          --                                                                    

  Non-chronic                       4                              0.689 (0.538 to 0.840)      0.0% and 0.935 and 0.001                                              

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        1                              0.700 (0.529 to 0.871)      --                                                                    

  Persistent                        2                              0.634 (0.308 to 0.960)      0.0% and 0.833 and 0.001                                              

  Permanent                         --                             --                          --                                                                    

                                                                                                                                                                     

  **RDW**                                                                                                                                                            

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                Yes, probably

  Asian                             1                              0.260 (0.065 to 0.455)      --                                                                    

  European                          6                              0.873 (0.806 to 0.941)      0.0% and 0.613 and 0.001                                              

  Africa                            \-                             --                          --                                                                    

  North American                    1                              0.280 (0.196 to 0.364)      --                                                                    

  South American                    \-                             --                          --                                                                    

  Australia                         \-                                                         --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                

  Cohort                            All of studies: case-control                                                                                                     

  Case-control                                                                                                                                                       

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             1                              0.500 (−0.039 to 1.039)     --                                                                    

  ≤300                              7                              0.615 (0.564 to 0.666)      95.5% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       Yes, probably

  \>60 years                        4                              0.412 (0.338 to 0.485)      92.8% and 0.001 and 0.001                                             

  ≤60 years                         3                              0.885 (0.809 to 0.961)      0.0% and 0.716 and 0.001                                              

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             1                              0.500 (−0.039 to 1.039)     --                                                                    

  ≤70%                              6                              0.641 (0.588 to 0.694)      95.8% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              No

  \>30%                             \-                             --                          --                                                                    

  ≤30%                              7                              0.640 (0.587 to 0.692)      95% and 0.001 and 0.001                                               

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   Yes, probably

  \>70%                             2                              0.856 (0.700 to 1.011)      0.0% and 0.337 and 0.001                                              

  ≤70%                              5                              0.612 (0.556 to 0.668)      96.4% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              No

  \>30%                             1                              0.500 (−0.039 to 1.039)     --                                                                    

  ≤30%                              3                              0.885 (0.809 to 0.961)      0.0% and 0.716 and 0.001                                              

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           

  \>70%                             No Data                                                                                                                          

  ≤70%                                                                                                                                                               

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             \-                             --                          --                                                                    

  ≤70%                              2                              1.021 (0.615 to 1.426)      0.0% and 0.636 and 0.001                                              

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             \-                             --                          --                                                                    

  ≤70%                              1                              0.500 (−0.039 to 1.039)     --                                                                    

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             \-                             --                          --                                                                    

  ≤70%                              3                              0.885 (0.809 to 0.961)      0.0% and 0.716 and 0.001                                              

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    Yes, probably

  1                                 \-                             --                          --                                                                    

  2                                 1                              0.500 (−0.039 to 1.039)     --                                                                    

  3                                 4                              0.875 (0.806 to 0.944)      0.0% and 0.796 and 0.001                                              

  4                                 \-                             --                          --                                                                    

  5                                 3                              0.297 (0.221 to 0.373)      80.7% and 0.006 and 0.001                                             

  6                                 \-                             --                          --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             No

  Chronic                           \-                             --                          --                                                                    

  Non-chronic                       4                              0.379 (0.310 to 0.448)      91.6% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        1                              0.260 (0.065 to 0.455)      --                                                                    

  Persistent                        \-                             --                          --                                                                    

  Permanent                         \-                             --                          --                                                                    

                                                                                                                                                                     

  **MCV**                                                                                                                                                            

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                No

  Asian                             1                              −0.300 (−1.364 to 0.764)    --                                                                    

  European                          1                              1.000 (−0.337 to 2.337)     --                                                                    

  Africa                            \-                             --                          --                                                                    

  North American                    1                              −0.280 (−0.706 to 0.146)    --                                                                    

  South American                    \-                             --                          --                                                                    

  Australia                         1                              1.000 (−0.998 to 2.998)     --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                

  Cohort                            All of studies: Case-control                                                                                                     

  Case-control                                                                                                                                                       

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             1                              −0.300 (−1.364 to 0.764)    --                                                                    

  ≤300                              3                              −0.116 (−0.514 to 0.283)    55% and 0.108 and 0.569                                               

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       No

  \>60 years                        2                              −0.283 (−0.679 to 0.113)    0.0% and 0.162 and 0.973                                              

  ≤60 years                         2                              1.000 (−0.111 to 2.111)     0.0% and 1.000 and 0.078                                              

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             1                              1.000 (−0.998 to 2.998)     --                                                                    

  ≤70%                              3                              −0.179 (−0.559 to 0.200)    38.5% and 0.197 and 0.354                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              No

  \>30%                             \-                             --                          --                                                                    

  ≤30%                              3                              −0.179 (−0.559 to 0.200)    38.5% and 0.197 and 0.354                                             

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   No

  \>70%                             \-                             --                          --                                                                    

  ≤70%                              3                              −0.179 (−0.559 to 0.200)    38.5% and 0.197 and 0.354                                             

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              No

  \>30%                             \-                             --                          --                                                                    

  ≤30%                              2                              0.204 (−0.628 to 1.037)     55% and 0.136 and 0.631                                               

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             \-                             --                          --                                                                    

  ≤70%                              1                              −0.300 (−1.364 to 0.764)    --                                                                    

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             \-                             --                          --                                                                    

  ≤70%                              1                              −0.300 (−1.364 to 0.764)    --                                                                    

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             \-                             --                          --                                                                    

  ≤70%                              1                              −0.300 (−1.364 to 0.764)    --                                                                    

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             \-                             --                          --                                                                    

  ≤70%                              2                              0.204 (−0.628 to 1.037)     55% and 0.136 and 0.631                                               

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    No

  1                                 --                             --                          --                                                                    

  2                                 --                             --                          --                                                                    

  3                                 1                              1.000 (−0.337 to 2.337)     --                                                                    

  4                                 1                              −0.300 (−1.364 to 0.764)    --                                                                    

  5                                 2                              −0.224 (−0.641 to 0.193)    33.7% and 0.219 and 0.292                                             

  6                                 --                             --                          --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             No

  Chronic                           --                             --                          --                                                                    

  Non-chronic                       1                              −0.280 (−0.706 to 0.146)    --                                                                    

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        --                             --                          --                                                                    

  Persistent                        --                             --                          --                                                                    

  Permanent                         --                             --                          --                                                                    

                                                                                                                                                                     

  **HCT**                                                                                                                                                            

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                No

  Asian                             --                             --                          --                                                                    

  European                          9                              0.552 (0.004 to 1.100)      53.4% and 0.028 and 0.048                                             

  Africa                            --                             --                          --                                                                    

  North American                    1                              2.670 (2.168 to 3.172)      --                                                                    

  South American                    --                             --                          --                                                                    

  Australia                         1                              3.000 (1.605 to 4.395)      --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                

  Cohort                            All of studies: Case-control                                                                                                     

  Case-control                                                                                                                                                       

                                                                                                                                                                     

  **Number of population**                                                                                                                                           

  \>300                             All of studies: ≤300                                                                                                             

  ≤300                                                                                                                                                               

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       No

  \>60 years                        10                             1.704 (1.334 to 2.075)      81.4% and 0.001 and 0.001                                             

  ≤60 years                         1                              3.000 (1.605 to 4.395)      --                                                                    

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             3                              1.666 (0.767 to 2.566)      67% and 0.048 and 0.001                                               

  ≤70%                              8                              1.813 (1.423 to 2.203)      84.6% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              No

  \>30%                             --                             --                          --                                                                    

  ≤30%                              8                              1.691 (1.299 to 2.083)      84.6% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              8                              1.691 (1.299 to 2.083)      84.6% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              No

  \>30%                             --                             --                          --                                                                    

  ≤30%                              5                              −0.064 (−0.805 to 0.678)    39.4% and 0.158 and 0.867                                             

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              4                              0.402 (−0.488 to 1.292)     0.0% and 0.753 and 0.376                                              

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              4                              0.402 (−0.488 to 1.292)     0.0% and 0.753 and 0.376                                              

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              4                              0.402 (−0.488 to 1.292)     0.0% and 0.753 and 0.376                                              

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              4                              0.402 (−0.488 to 1.292)     0.0% and 0.753 and 0.376                                              

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    Yes, probably

  1                                 2                              1.819 (0.693 to 2.945)      65.9% and 0.087 and 0.002                                             

  2                                 --                             --                          --                                                                    

  3                                 2                              −0.021 (−1.381 to 1.340)    0.0% and 0.477 and 0.976                                              

  4                                 4                              0.852 (0.001 to 1.704)      0.0% and 0.985 and 0.050                                              

  5                                 3                              2.230 (1.787 to 2.673)      93.9% and 0.001 and 0.001                                             

  6                                 --                             --                          --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             No

  Chronic                           5                              0.062 (−0.635 to 0.759)     46.9% and 0.110 and 0.861                                             

  Non-chronic                       3                              2.611 (2.141 to 3.082)      18.5% and 0.293 and 0.001                                             

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        1                              1.000 (−1.122 to 3.122)     --                                                                    

  Persistent                        --                             --                          --                                                                    

  Permanent                         4                              0.617 (−0.215 to 1.450)     0.0% and 0.603 and 0.146                                              

                                                                                                                                                                     

  **Hb**                                                                                                                                                             

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            No

  \>2000                            25                             0.024 (−0.038 to 0.087)     91.1% and 0.001 and 0.444                                             

  ≤2000                             2                              1.076 (0.522 to 1.630)      85.2% and 0.009 and 0.001                                             

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                Yes, probably

  Asian                             2                              −0.048 (−0.366 to 0.271)    0.0% and 0.758 and 0.769                                              

  European                          21                             −0.150 (−0.219 to −0.081)   76.8% and 0.001 and 0.001                                             

  Africa                            --                             --                          --                                                                    

  North American                    4                              0.994 (0.840 to 1.149)      89.4% and 0.001 and 0.001                                             

  South American                    --                             --                          --                                                                    

  Australia                         --                             --                          --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                Yes, probably

  Cohort                            6                              −0.093 (−0.142 to −0.044)   0.0% and 0.488 and 0.001                                              

  Case-control                      21                             0.102 (0.024 to 0.181)      92.8% and 0.001 and 0.011                                             

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             1                              −0.100 (−0.643 to 0.443)    --                                                                    

  ≤300                              26                             0.039 (−0.023 to 0.102)     91.4% and 0.001 and 0.216                                             

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       No

  \>60 years                        20                             0.033 (−0.032 to 0.098)     92.5% and 0.001 and 0.317                                             

  ≤60 years                         5                              −0.077 (−0.297 to 0.143)    73.5% and 0.005 and 0.494                                             

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             6                              −0.040 (−0.143 to 0.063)    75.1% and 0.001 and 0.447                                             

  ≤70%                              19                             0.062 (−0.017 to 0.140)     92.7% and 0.001 and 0.123                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              Yes, probably

  \>30%                             2                              −0.048 (−0.366 to 0.271)    0.0% and 0.758 and 0.769                                              

  ≤30%                              23                             0.027 (−0.036 to 0.091)     91.8% and 0.001 and 0.401                                             

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   Yes, probably

  \>70%                             2                              −0.275 (−0.481 to 0.070)    0.0% and 0.583 and 0.009                                              

  ≤70%                              23                             0.055 (−0.011 to 0.120)     91.6% and 0.001 and 0.102                                             

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              Yes, probably

  \>30%                             8                              −0.054 (−0.223 to 0.114)    0.0% and 0.597 and 0.529                                              

  ≤30%                              10                             −0.308 (−0.422 to −0.193)   80.8% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              9                              −0.184 (−0.267 to −0.100)   84.9% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              13                             −0.192 (−0.272 to −0.112)   80.6% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              10                             −0.017 (−0.114 to 0.079)    58% and 0.011 and 0.729                                               

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              14                             −0.172 (−0.251 to −0.094)   80.8% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    No

  1                                 2                              1.076 (0.522 to 1.630)      85.2% and 0.009 and 0.001                                             

  2                                 1                              −0.100 (−0.643 to 0.443)    --                                                                    

  3                                 6                              −0.183 (−0.355 to −0.011)   73.3% and 0.002 and 0.037                                             

  4                                 9                              −0.005 (−0.100 to 0.090)    63.2% and 0.005 and 0.913                                             

  5                                 8                              0.148 (0.049 to 0.247)      96.8% and 0.001 and 0.004                                             

  6                                 1                              −0.200 (−0.550 to 0.150)    --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             No

  Chronic                           8                              −0.320 (−0.443 to −0.196)   85.2% and 0.001 and 0.001                                             

  Non-chronic                       5                              0.543 (0.418 to 0.668)      96.1% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        1                              0.500 (−0.059 to 1.059)     --                                                                    

  Persistent                        1                              0.200 (−0.553 to 0.953)     --                                                                    

  Permanent                         4                              −0.458 (−0.596 to −0.320)   68.5% and 0.023 and 0.001                                             

                                                                                                                                                                     

  **Occurrence of AF**                                                                                                                                               

                                                                                                                                                                     

  **Platelet count**                                                                                                                                                 

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                Yes, probably

  Asian                             2                              14.48 (−1.95 to 30.91)      28.6% and 0.237 and 0.084                                             

  European                          2                              −12.96 (−25.66 to −0.272)   40.8% and 0.194 and 0.045                                             

  Africa                            --                             --                          --                                                                    

  North American                    --                             --                          --                                                                    

  South American                    --                             --                          --                                                                    

  Australia                         --                             --                          --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                No

  Cohort                            3                              0.217 (−0.188 to 0.622)     50.9% and 0.130 and 0.294                                             

  Case-control                      1                              20.45 (1.27 to 39.63)       --                                                                    

                                                                                                                                                                     

  **Number of population**                                                                                                                                           

  \>300                             All of studies: ≤300                                                                                                             

  ≤300                                                                                                                                                               

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       No

  \>60 years                        3                              −0.132 (−13.084 to 12.82)   78.8% and 0.009 and 0.984                                             

  ≤60 years                         1                              −6.60 (−22.517 to 9.317)    --                                                                    

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              3                              −2.78 (−13.37 to 7.79)      79.6% and 0.007 and 0.606                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              

  \>30%                             All of studies: ≤30%                                                                                                             

  ≤30%                                                                                                                                                               

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   

  \>70%                             All of studies: ≤70%                                                                                                             

  ≤70%                                                                                                                                                               

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              Yes, probably

  \>30%                             2                              4.43 (−7.81 to 16.80)       77.9% and 0.033 and 0.478                                             

  ≤30%                              2                              −17.38 (−34.94 to 0.174)    22.3% and 0.257 and 0.052                                             

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           

  \>70%                             No Data                                                                                                                          

  ≤70%                                                                                                                                                               

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              2                              0.238 (−13.93 to 14.41)     89.4% and 0.002 and 0.974                                             

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              3                              −0.132 (−13.08 to 12.82)    78.8% and 0.009 and 0.984                                             

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              2                              0.238 (−13.93 to 14.41)     89.4% and 0.002 and 0.974                                             

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    Yes, probably

  1                                 --                             --                          --                                                                    

  2                                 --                             --                          --                                                                    

  3                                 --                             --                          --                                                                    

  4                                 2                              4.432 (−7.817 to 16.68)     77.9% and 0.033 and 0.478                                             

  5                                 2                              −17.38 (−34.94 to 0.174)    22.3% and 0.257 and 0.052                                             

  6                                 --                             --                          --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             

  Chronic                           All of studies: non--chronic                                                                                                     

  Non-chronic                                                                                                                                                        

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        2                              0.238 (−13.93 to 14.41)     89.4% and 0.002 and 0.974                                             

  Persistent                        --                             --                          --                                                                    

  Permanent                         --                             --                          --                                                                    

                                                                                                                                                                     

  **WBC**                                                                                                                                                            

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                Yes, probably

  Asian                             11                             0.136 (−0.013 to 0.284)     34.7% and 0.121 and 0.073                                             

  European                          11                             0.347 (0.120 to 0.574)      65.1% and 0.001 and 0.003                                             

  Africa                            --                             --                          --                                                                    

  North American                    --                             --                          --                                                                    

  South American                    --                             --                          --                                                                    

  Australia                         --                             --                          --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                Yes, probably

  Cohort                            20                             0.202 (0.077 to 0.326)      58.6% and 0.001 and 0.002                                             

  Case-control                      2                              −0.344 (−2.282 to 1.594)    0.0% and 0.710 and 0.728                                              

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             3                              0.146 (−0.030 to 0.321)     63.6% and 0.064 and 0.103                                             

  ≤300                              19                             0.254 (0.077 to 0.430)      55.1% and 0.002 and 0.005                                             

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       Yes, probably

  \>60 years                        10                             0.097 (−0.076 to 0.269)     0.0% and 0.498 and 0.272                                              

  ≤60 years                         12                             0.310 (0.131 to 0.489)      68.7% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             9                              0.251 (0.093 to 0.410)      49.4% and 0.045 and 0.002                                             

  ≤70%                              11                             0.107 (−0.108 to 0.323)     62.4% and 0.003 and 0.328                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              No

  \>30%                             --                             --                          --                                                                    

  ≤30%                              17                             0.286 (0.149 to 0.423)      55.7% and 0.003 and 0.001                                             

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   No

  \>70%                             1                              −0.030 (−0.560 to 0.50)     --                                                                    

  ≤70%                              20                             0.215 (0.087 to 0.344)      58.1% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              Yes, probably

  \>30%                             5                              0.707 (0.376 to 1.037)      63% and 0.029 and 0.001                                               

  ≤30%                              6                              0.032 (−0.261 to 0.325)     0.0% and 0.416 and 0.832                                              

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             1                              −0.40 (−1.087 to 0.287)     --                                                                    

  ≤70%                              3                              0.202 (−0.012 to 0.417)     0.0% and 0.776 and 0.064                                              

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              13                             0.217 (0.067 to 0.367)      68.8% and 0.001 and 0.005                                             

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              11                             0.321 (0.117 to 0.525)      71.9% and 0.001 and 0.002                                             

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             2                              −0.159 (−0.654 to 0.335)    0.0% and 0.322 and 0.528                                              

  ≤70%                              7                              0.083 (−0.087 to 0.252)     42.1% and 0.110 and 0.339                                             

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    Yes, probably

  1                                 --                             --                          --                                                                    

  2                                 4                              −0.097 (−0.476 to 0.282)    0.0% and 0.860 and 0.617                                              

  3                                 --                             --                          --                                                                    

  4                                 2                              0.341 (−0.269 to 0.952)     0.0% and 0.482 and 0.273                                              

  5                                 16                             0.230 (0.095 to 0.365)      64.5% and 0.001 and 0.001                                             

  6                                 --                             --                          --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             No

  Chronic                           --                             --                          --                                                                    

  Non-chronic                       21                             0.181 (0.049 to 0.314)      56.3% and 0.001 and 0.007                                             

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        7                              −0.036 (−0.291 to 0.218)    25.6% and 0.233 and 0.781                                             

  Persistent                        7                              −0.077 (−0.383 to 0.229)    0.0% and 0.887 and 0.621                                              

  Permanent                         --                             --                          --                                                                    

                                                                                                                                                                     

  **NLR**                                                                                                                                                            

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                Yes, probably

  Asian                             3                              0.047 (−0.124 to 0.218)     0.0% and 0.552 and 0.588                                              

  European                          4                              0.750 (0.565 to 0.936)      35.1% and 0.201 and 0.001                                             

  Africa                            --                             --                          --                                                                    

  North American                    --                             --                          --                                                                    

  South American                    --                             --                          --                                                                    

  Australia                         --                             --                          --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                

  Cohort                            All of studies: cohort                                                                                                           

  Case-control                                                                                                                                                       

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             2                              0.035 (−0.142 to 0.212)     0.0% and 0.340 and 0.698                                              

  ≤300                              5                              0.712 (0.533 to 0.891)      41.9% and 0.142 and 0.001                                             

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       Yes, probably

  \>60 years                        3                              0.476 (0.183 to 0.770)      21.4% and 0.280 and 0.001                                             

  ≤60 years                         4                              0.346 (0.207 to 0.485)      90.8% and 0.001 and 0.001                                             

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             2                              0.035 (−0.142 to 0.212)     0.0% and 0.340 and 0.698                                              

  ≤70%                              3                              0.804 (0.610 to 0.997)      0.0% and 0.593 and 0.001                                              

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              

  \>30%                             All of studies: ≤30%                                                                                                             

  ≤30%                                                                                                                                                               

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   

  \>70%                             All of studies: ≤70%                                                                                                             

  ≤70%                                                                                                                                                               

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              No

  \>30%                             2                              0.851 (0.626 to 1.077)      0.0% and 0.530 and 0.001                                              

  ≤30%                              3                              0.476 (0.183 to 0.770)      21.4% and 0.280 and 0.001                                             

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           

  \>70%                             No data                                                                                                                          

  ≤70%                                                                                                                                                               

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              2                              0.819 (0.615 to 1.023)      0.0% and 0.360 and 0.001                                              

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              3                              0.767 (0.572 to 0.963)      45.6% and 0.159 and 0.001                                             

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             --                             0.670 (0.291 to 1.049)      --                                                                    

  ≤70%                              1                                                          --                                                                    

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    No

  1                                 --                             --                          --                                                                    

  2                                 1                              0.150 (−0.499 to 0.799)     --                                                                    

  3                                 --                             --                          --                                                                    

  4                                 --                             --                          --                                                                    

  5                                 6                              0.379 (0.250 to 0.507)      --                                                                    

  6                                 --                             --                          --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             No

  Chronic                           --                             --                          --                                                                    

  Non-chronic                       6                              0.527 (0.370 to 0.684)      80% and 0.001 and 0.001                                               

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        2                              0.670 (0.349 to 0.991)      0.0% and 1.000 and 0.001                                              

  Persistent                        1                              0.150 (−0.499 to 0.799)     --                                                                    

  Permanent                         --                             --                          --                                                                    

                                                                                                                                                                     

  **RDW**                                                                                                                                                            

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                Yes, probably

  Asian                             3                              0.165 (0.051 to 0.279)      79.1% and 0.008 and 0.005                                             

  European                          2                              0.803 (0.560 to 1.045)      0.0% and 0.425 and 0.001                                              

  Africa                            --                             --                          --                                                                    

  North American                    --                             --                          --                                                                    

  South American                    --                             --                          --                                                                    

  Australia                         --                             --                          --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                No

  Cohort                            4                              0.264 (0.155 to 0.372)      90.3% and 0.001 and 0.001                                             

  Case-control                      1                              0.440 (0.102 to 0.778)      --                                                                    

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             1                              0.100 (−0.023 to 0.223)     --                                                                    

  ≤300                              4                              0.705 (0.516 to 0.894)      31.2% and 0.225 and 0.001                                             

                                                                                                                                                                     

  **Mean age**                                                                                                                                                       Yes, probably

  \>60 years                        3                              0.165 (0.051 to 0.279)      79.1% and 0.008 and 0.005                                             

  ≤60 years                         2                              0.803 (0.560 to 1.045)      0.0% and 0.425 and 0.001                                              

                                                                                                                                                                     

  **Male**                                                                                                                                                           Yes, probably

  \>70%                             2                              0.129 (0.008 to 0.250)      85.1% and 0.010 and 0.036                                             

  ≤70%                              3                              0.680 (0.483 to 0.877)      43.8% and 0.169 and 0.001                                             

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              

  \>30%                             All of studies: ≤30%                                                                                                             

  ≤30%                                                                                                                                                               

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   

  \>70%                             ≤70%                                                                                                                             

  ≤70%                                                                                                                                                               

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              No

  \>30%                             3                              0.680 (0.483 to 0.877)      43.8% and 0.169 and 0.001                                             

  ≤30%                              --                             --                          --                                                                    

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             1                              (0.329 to 1.671)            --                                                                    

  ≤70%                              1                              0.100 (−0.023 to 0.223)     --                                                                    

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              3                              0.165 (0.051 to 0.279)      79.1% and 0.008 and 0.005                                             

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              1                              0.440 (0.102 to 0.778)      --                                                                    

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             1                              1.000 (0.329 to 1.671)      --                                                                    

  ≤70%                              2                              0.140 (0.024 to 0.255)      70.8% and 0.064 and 0.018                                             

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    No

                                                                                                                                                                     

  1                                 --                             --                          --                                                                    

  2                                 --                             --                          --                                                                    

  3                                 --                             --                          --                                                                    

  4                                 2                              0.661 (0.460 to 0.861)      60.3% and 0.113 and 0.001                                             

  5                                 3                              0.143 (0.023 to 0.263)      81.2% and 0.005 and 0.020                                             

  6                                 --                             --                          --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             

  Chronic                           All of studies: non--chronic                                                                                                     

  Non-chronic                                                                                                                                                        

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        2                              0.511 (0.188 to 0.834)      46.9% and 0.170 to 0.002                                              

  Persistent                        --                             --                          --                                                                    

  Permanent                         --                             --                          --                                                                    

                                                                                                                                                                     

  **Hb**                                                                                                                                                             

                                                                                                                                                                     

  **Year of publication**                                                                                                                                            

  \>2000                            All of studies: after 2000                                                                                                       

  ≤2000                                                                                                                                                              

                                                                                                                                                                     

  **Geographic area**                                                                                                                                                No

  Asian                             5                              0.046 (−0.133 to 0.226)     43.2% and 0.133 and 0.613                                             

  European                          4                              0.007 (−0.306 to 0.319)     0.0% and 0.539 and 0.967                                              

  Africa                            --                             --                          --                                                                    

  North American                    --                             --                          --                                                                    

  South American                    --                             --                          --                                                                    

  Australia                         --                             --                          --                                                                    

                                                                                                                                                                     

  **Design of study**                                                                                                                                                No

  Cohort                            8                              0.029 (−0.131 to 0.189)     23.1% and 0.246 and 0.723                                             

  Case-control                      1                              0.170 (−0.506 to 0.846)     --                                                                    

                                                                                                                                                                     

  **Number of population**                                                                                                                                           No

  \>300                             2                              0.095 (−0.099 to 0.288)     54.4% and 0.139 and 0.336                                             

  ≤300                              7                              −0.070 (−0.331 to 0.191)    1.2% and 0.451 and 0.598                                              

                                                                                                                                                                     

  **Mean Age**                                                                                                                                                       No

  \>60 years                        5                              −0.057 (−0.258 to 0.144)    3.0% and 0.390 and 0.576                                              

  ≤60 years                         4                              0.177 (−0.069 to 0.422)     1.5% and 0.385 and 0.159                                              

                                                                                                                                                                     

  **Male**                                                                                                                                                           No

  \>70%                             3                              0.056 (−0.133 to 0.245)     65.4% and 0.056 and 0.563                                             

  ≤70%                              5                              0.035 (−0.248 to 0.319)     0.0% and 0.672 and 0.807                                              

                                                                                                                                                                     

  **Diabetes mellitus**                                                                                                                                              

  \>30%                             All of studies: ≤30%                                                                                                             

  ≤30%                                                                                                                                                               

                                                                                                                                                                     

  **Hypertension**                                                                                                                                                   

  \>70%                             All of studies: ≤70%                                                                                                             

  ≤70%                                                                                                                                                               

                                                                                                                                                                     

  **Cigarette smoking**                                                                                                                                              No

  \>30%                             4                              0.070 (−0.233 to 0.374)     0.0% and 0.582 and 0.650                                              

  ≤30%                              2                              −0.314 (−0.933 to 0.306)    0.0% and 0.645 and 0.321                                              

                                                                                                                                                                     

  **Medication: Diuretic**                                                                                                                                           No

  \>70%                             1                              −0.800 (−1.706 to 0.106)    --                                                                    

  ≤70%                              1                              0.00 (−0.231 to 0.231)      --                                                                    

                                                                                                                                                                     

  **Medication: ACEI**                                                                                                                                               No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              5                              −0.047 (−0.238 to 0.144)    0.0% and 0.494 and 0.630                                              

                                                                                                                                                                     

  **Medication: Statin**                                                                                                                                             No

  \>70%                             --                             --                          --                                                                    

  ≤70%                              4                              −0.096 (−0.442 to 0.250)    0.0% and 0.734 and 0.587                                              

                                                                                                                                                                     

  **Medication: Beta-Blocker**                                                                                                                                       No

  \>70%                             1                              −0.800 (−1.706 to 0.106)    --                                                                    

  ≤70%                              3                              0.002 (−0.208 to 0.213)     0.0% and 0.782 and 0.984                                              

                                                                                                                                                                     

  **Anti-coagulant status codes**                                                                                                                                    No

  1                                 --                             --                          --                                                                    

  2                                 --                             --                          --                                                                    

  3                                 --                             --                          --                                                                    

  4                                 2                              0.236 (−0.161 to 0.632)     0.0% and 0.814 and 0.244                                              

  5                                 7                              0.00 (−0.169 to 0.169)      25.5% and 0.234 and 0.998                                             

  6                                 --                             --                          --                                                                    

                                                                                                                                                                     

  **AF**                                                                                                                                                             No

  Chronic                           --                             --                          --                                                                    

  Non-chronic                       8                              −0.031 (−0.204 to 0.142)    0.0% and 0.513 and 0.727                                              

                                                                                                                                                                     

  **Type of AF**                                                                                                                                                     No

  Paroxysmal                        3                              −0.070 (−0.531 to 0.391)    0.0% and 0.603 and 0.766                                              

  Persistent                        --                             --                          --                                                                    

  Permanent                         --                             --                          --                                                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Source of support:** Departmental sources
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###### 

Characteristics of included studies for meta-analysis of association of hematologic parameters with AF.

  First Author                                                                   Year   Country       Design         N-AF   N-SR   Age-AF   Age-SR   Male-AF   Male-SR   AC-AF   AC-SR   Type of AF       NOS
  ------------------------------------------------------------------------------ ------ ------------- -------------- ------ ------ -------- -------- --------- --------- ------- ------- ---------------- -----
  **Occurrence of AF**                                                                                                                                                                                    
  Balci (Male subjects) \[[@b8-medscimonitbasicres-23-179]\]                     2016   Turkey        Case-control   18     17     ND       ND       100       100       ND      ND      ND               8
  Balci (Female subjects) \[[@b8-medscimonitbasicres-23-179]\]                   2016   Turkey        Case-control   65     88     ND       ND       0         0         ND      ND      ND               8
  Gurses \[[@b9-medscimonitbasicres-23-179]\]                                    2016   Turkey        Case-control   86     86     56.6     56.4     51.2      53.5      ND      ND      Combined types   9
  Karatas \[[@b10-medscimonitbasicres-23-179]\]                                  2016   Turkey        Case-control   40     581    65.7     56.4     70        75        100     100     ND               8
  Korantzopoulos \[[@b11-medscimonitbasicres-23-179]\]                           2016   Greece        Case-control   32     69     78       75       47        46        60      0       Combined types   9
  Akdag \[[@b12-medscimonitbasicres-23-179]\]                                    2015   Turkey        Case-control   96     52     63.6     64.5     64        56        54.16   ND      Combined types   9
  Akyuz \[[@b13-medscimonitbasicres-23-179]\]                                    2015   Turkey        Case-control   40     50     63       61.5     72.5      72        20      14      Combined types   7
  Chavaria \[[@b14-medscimonitbasicres-23-179]\]                                 2015   USA           Cohort         40     250    70.6     60.7     65        84        ND      ND      ND               6
  Drabik (Persistent AF) \[[@b15-medscimonitbasicres-23-179]\]                   2015   Poland        Case-control   47     50     60.8     59.4     65.95     64        38.3    26      Persistent       9
  Drabik (Paroxysmal AF) \[[@b15-medscimonitbasicres-23-179]\]                   2015   Poland        Case-control   41     50     60.6     59.4     46.3      64        51.2    26      Paroxysmal       9
  Acet (Paroxysmal AF) \[[@b16-medscimonitbasicres-23-179]\]                     2014   Turkey        Case-control   71     63     63       61.1     42        46        ND      ND      Paroxysmal       9
  Acet (Persistent and permanent AF) \[[@b16-medscimonitbasicres-23-179]\]       2014   Turkey        Case-control   63     63     64.6     61.1     41        46        ND      ND      Combined types   9
  Arik (effective INR) \[[@b17-medscimonitbasicres-23-179]\]                     2014   Turkey        Case-control   125    123    70.4     68.9     41.6      39.8      ND      ND      Permanent        8
  Arik (ineffective INR) \[[@b17-medscimonitbasicres-23-179]\]                   2014   Turkey        Case-control   125    123    70       68.9     36        39.8      ND      ND      Permanent        8
  Distelmaier \[[@b18-medscimonitbasicres-23-179]\]                              2014   USA           Case-control   66     132    73.5     73.5     61        61        ND      ND      ND               7
  Erdogan (with normal ventricular rate) \[[@b19-medscimonitbasicres-23-179]\]   2014   Turkey        Case-control   34     33     70.5     68.6     47.05     51.51     66.6    0       Permanent        10
  Erdogan (with high ventricular rate) \[[@b19-medscimonitbasicres-23-179]\]     2014   Turkey        Case-control   30     33     69       68.6     46.6      51.51     83.3    0       Permanent        10
  Zheng \[[@b20-medscimonitbasicres-23-179]\]                                    2014   China         Case-control   117    100    64.37    59.1     57.26     60        ND      ND      ND               8
  Xu (without thrombotic events) \[[@b21-medscimonitbasicres-23-179]\]           2014   China         Cohort         57     58     65.19    67       50.9      50        50.9    15.5    ND               7
  Xu (with thrombotic events) \[[@b21-medscimonitbasicres-23-179]\]              2014   China         Cohort         57     58     68.95    67       52.6      50        49.1    15.5    ND               7
  Gungor \[[@b22-medscimonitbasicres-23-179]\]                                   2014   Turkey        Case-control   117    60     48.3     46.1     60.6      55        75.2    8.3     Combined types   9
  Liu \[[@b23-medscimonitbasicres-23-179]\]                                      2014   China         Case-control   133    101    ND       ND       ND        ND        ND      ND      Paroxysmal       8
  Sarikaya \[[@b24-medscimonitbasicres-23-179]\]                                 2014   Turkey        Case-control   63     63     71.09    70.97    47.8      52.2      ND      ND      ND               8
  Sonmez \[[@b25-medscimonitbasicres-23-179]\]                                   2014   Turkey        Case-control   52     33     70       70       34.61     39.39     59.61   36.36   Persistent       8
  Ulu \[[@b26-medscimonitbasicres-23-179]\]                                      2014   Turkey        Case-control   25     32     ND       ND       ND        ND        ND      ND      ND               7
  Berge \[[@b27-medscimonitbasicres-23-179]\]                                    2013   Norway        Cohort         63     126    75       75       71.42     70.63     8       33      Combined types   9
  Ertas (without stroke) \[[@b28-medscimonitbasicres-23-179]\]                   2013   Turkey        Case-control   87     24     69       38       44        58        58      0       ND               6
  Ertas (with stroke) \[[@b28-medscimonitbasicres-23-179]\]                      2013   Turkey        Case-control   39     24     71       38       36        58        51      0       ND               6
  Gungor \[[@b29-medscimonitbasicres-23-179]\]                                   2013   Turkey        Case-control   70     70     42.2     42.9     68.5      64.3      ND      ND      Combined types   7
  Turgut \[[@b30-medscimonitbasicres-23-179]\]                                   2013   Turkey        Case-control   81     81     64       62       51        53        28      20      ND               7
  Jaremo (healthy control) \[[@b31-medscimonitbasicres-23-179]\]                 2013   Sweden        Cohort         58     24     69       66       79.3      54.16     12.06   0       ND               8
  Jaremo (disease control) \[[@b31-medscimonitbasicres-23-179]\]                 2013   Sweden        Cohort         58     72     69       74       79.3      56.9      12.06   41.66   ND               8
  Sahin \[[@b32-medscimonitbasicres-23-179]\]                                    2013   Turkey        Case-control   72     72     65.01    64.72    48.2      51.3      ND      ND      Persistent       7
  Tekin \[[@b33-medscimonitbasicres-23-179]\]                                    2013   Turkey        Case-control   107    112    74       73       31        40        ND      ND      ND               7
  Turfan (without stroke) \[[@b34-medscimonitbasicres-23-179]\]                  2013   Turkey        Cohort         77     58     63       56       57.4      51.7      44.3    0       ND               7
  Turfan (with stroke) \[[@b34-medscimonitbasicres-23-179]\]                     2013   Turkey        Cohort         63     58     69       56       52.4      51.7      41.3    0       ND               7
  Feng \[[@b35-medscimonitbasicres-23-179]\]                                     2012   China         Case-control   185    189    65.9     65.7     62.7      60.8      76.8    83.1    Combined types   8
  Liu (Paroxysmal AF) \[[@b36-medscimonitbasicres-23-179]\]                      2012   China         Cohort         50     51     64.3     64.4     64        61        100     0       Paroxysmal       8
  Liu (Persistent AF) \[[@b36-medscimonitbasicres-23-179]\]                      2012   China         Cohort         56     51     67.2     64.4     61        61        100     0       Persistent       8
  Yoshizaki \[[@b37-medscimonitbasicres-23-179]\]                                2012   Japan         Cohort         24     152    74       66       75        77        ND      ND      ND               8
  Hayashi (Paroxysmal AF) \[[@b38-medscimonitbasicres-23-179]\]                  2011   Japan         Case-control   14     13     53.1     62.8     93        92        100     100     Paroxysmal       7
  Hayashi (Chronic AF) \[[@b38-medscimonitbasicres-23-179]\]                     2011   Japan         Case-control   14     13     60.1     62.8     93        92        100     100     ND               7
  Fu \[[@b39-medscimonitbasicres-23-179]\]                                       2011   China         Case-control   90     79     54.1     54.8     70        57        22      0       Combined types   8
  Liu \[[@b40-medscimonitbasicres-23-179]\]                                      2011   China         Case-control   50     401    61.8     54.9     54        48.87     ND      ND      Combined types   8
  Letsas (Paroxysmal AF) \[[@b41-medscimonitbasicres-23-179]\]                   2010   Greece        Case-control   45     48     67.4     61.3     62        56        ND      ND      Paroxysmal       9
  Letsas (Permanent AF) \[[@b41-medscimonitbasicres-23-179]\]                    2010   Greece        Case-control   41     48     71.9     61.3     63        56        ND      ND      Permanent        9
  Luan (Persistent AF) \[[@b42-medscimonitbasicres-23-179]\]                     2010   China         Case-control   27     26     62.04    44.46    55.56     46.15     ND      ND      Persistent       8
  Luan (Paroxysmal AF) \[[@b42-medscimonitbasicres-23-179]\]                     2010   China         Case-control   29     26     57.52    44.46    58.62     46.15     ND      ND      Paroxysmal       8
  Alberti \[[@b43-medscimonitbasicres-23-179]\]                                  2009   Italy         Case-control   17     34     68.1     60.8     47.05     47.05     0       0       Persistent       7
  Dai \[[@b44-medscimonitbasicres-23-179]\]                                      2009   China         Case-control   242    280    56.09    50.04    79.8      69.6      ND      ND      Combined types   8
  Ichiki \[[@b45-medscimonitbasicres-23-179]\]                                   2009   Japan         Case-control   48     24     54       49       81.25     79.16     ND      ND      Paroxysmal       9
  Yao (Persistent AF) \[[@b46-medscimonitbasicres-23-179]\]                      2009   China         Case-control   72     78     55.4     52.8     79.2      74.4      15.3    7.7     Persistent       7
  Yao (Paroxysmal AF) \[[@b46-medscimonitbasicres-23-179]\]                      2009   China         Case-control   261    78     53.9     52.8     75.5      74.4      12.3    7.7     Paroxysmal       7
  Colkesen \[[@b47-medscimonitbasicres-23-179]\]                                 2008   Turkey        Case-control   103    87     63       45       55        21        50      14      Paroxysmal       8
  Choudhury (disease control) \[[@b48-medscimonitbasicres-23-179]\]              2008   UK            case-control   121    71     62.58    64.04    76        72        37.2    47.4    ND               6
  Choudhury (healthy control) \[[@b48-medscimonitbasicres-23-179]\]              2008   UK            case-control   121    56     62.58    62.03    76        68        37.2    0       ND               6
  Pirat \[[@b49-medscimonitbasicres-23-179]\]                                    2007   Turkey        Case-control   18     21     53       46       55        48        ND      ND      ND               7
  Yip \[[@b50-medscimonitbasicres-23-179]\]                                      2006   Taiwan        Case-control   62     20     66.2     65.3     66.1      60        58.1    0       ND               9
  Kamath (Paroxysmal and persistent AF) \[[@b51-medscimonitbasicres-23-179]\]    2003   UK            Case-control   31     31     61       66       61.3      41.9      0       0       Combined types   6
  Kamath (Permanent AF) \[[@b51-medscimonitbasicres-23-179]\]                    2003   UK            Case-control   93     31     66       66       63.4      41.9      0       0       Permanent        6
  Kamath (Paroxysmal AF) \[[@b52-medscimonitbasicres-23-179]\]                   2002   UK            Case-control   29     29     61       65       55.17     41.37     37.9    0       Paroxysmal       7
  Kamath (Permanent AF) \[[@b52-medscimonitbasicres-23-179]\]                    2002   UK            Case-control   87     29     65       65       63.21     41.37     37.9    0       Permanent        7
  Kamath \[[@b53-medscimonitbasicres-23-179]\]                                   2002   UK            Case-control   93     50     70       70       62.36     46        0       0       ND               6
  Kamath \[[@b54-medscimonitbasicres-23-179]\]                                   2002   UK            Case-control   34     23     73       ND       50        ND        0       0       ND               6
  Peverill \[[@b55-medscimonitbasicres-23-179]\]                                 2001   Australia     Case-control   79     84     63       47       83.5      85.7      ND      ND      ND               8
  Kahn (without stroke) \[[@b56-medscimonitbasicres-23-179]\]                    1997   Canada        Case-control   50     31     ND       65       ND        38.7      0       0       ND               7
  Kahn (with stroke) \[[@b56-medscimonitbasicres-23-179]\]                       1997   Canada        Case-control   25     11     ND       65       ND        63.6      0       0       ND               7
  Lip \[[@b57-medscimonitbasicres-23-179]\]                                      1996   UK            Case-control   51     26     70.4     ND       ND        ND        0       0       ND               6
  Gustafsson (without stroke) \[[@b58-medscimonitbasicres-23-179]\]              1990   Sweden        Case-control   20     20     77       77       ND        ND        0       0       ND               8
  Gustafsson (with stroke) \[[@b58-medscimonitbasicres-23-179]\]                 1990   Sweden        Case-control   20     20     77       77       ND        ND        0       0       ND               8
  **Recurrence of AF**                                                                                                                                                                                    
  Gurses \[[@b9-medscimonitbasicres-23-179]\]                                    2016   Turkey        Case-control   12     74     57.5     56.1     66.7      48.7      ND      ND      Combined types   9
  Hongliang Li \[[@b59-medscimonitbasicres-23-179]\]                             2016   China         Case-control   35     69     62       63       40        47.8      51.4    52.2    Paroxysmal       7
  Yanagisawa (without heart failure) \[[@b60-medscimonitbasicres-23-179]\]       2016   Japan         Cohort         269    409    61.1     61.1     77        75        ND      ND      Combined types   7
  Yanagisawa (with heart failure) \[[@b60-medscimonitbasicres-23-179]\]          2016   Japan         Cohort         42     37     64.2     63       62        87        ND      ND      Combined types   7
  Aksu \[[@b61-medscimonitbasicres-23-179]\]                                     2015   Turkey        Cohort         7      42     65.01    54.29    57        48        ND      ND      Paroxysmal       9
  Gurses \[[@b62-medscimonitbasicres-23-179]\]                                   2015   Turkey        Cohort         70     229    56.3     55.1     58.6      43.7      48.57   34.11   Combined types   9
  Karavelioglu \[[@b63-medscimonitbasicres-23-179]\]                             2015   Turkey        Cohort         87     131    65.8     63       35.63     46.56     ND      ND      Paroxysmal       7
  Wen \[[@b64-medscimonitbasicres-23-179]\]                                      2015   China         Cohort         15     60     63.67    63.57    ND        ND        ND      ND      Combined types   9
  Guo Xueyuan \[[@b65-medscimonitbasicres-23-179]\]                              2014   China         Cohort         124    255    49.6     49.73    72.9      74.2      ND      ND      ND               9
  Aribas \[[@b66-medscimonitbasicres-23-179]\]                                   2013   Turkey        Cohort         46     103    61       59       ND        ND        100     100     Persistent       9
  Bing Li \[[@b67-medscimonitbasicres-23-179]\]                                  2013   China         Cohort         80     208    56       58       72.5      69.7      ND      ND      Paroxysmal       9
  Canpolat \[[@b68-medscimonitbasicres-23-179]\]                                 2013   Turkey        Cohort         60     191    57.3     53.1     60        49.7      ND      ND      ND               8
  Im \[[@b69-medscimonitbasicres-23-179]\]                                       2013   South Korea   Cohort         107    392    56.5     56.3     73.8      73.5      ND      ND      Combined types   9
  Xiao-nan HE \[[@b70-medscimonitbasicres-23-179]\]                              2013   China         Cohort         106    224    60       59       62.4      70.2      ND      ND      Paroxysmal       6
  Ferro \[[@b71-medscimonitbasicres-23-179]\]                                    2012   Italy         Cohort         50     94     70.3     71.6     52        61        100     100     Persistent       8
  Smit \[[@b72-medscimonitbasicres-23-179]\]                                     2012   Netherland    Cohort         30     70     63       65       73.3      74.3      ND      ND      Persistent       7
  Wang (Paroxysmal AF) \[[@b73-medscimonitbasicres-23-179]\]                     2012   China         Cohort         41     62     58       57       32.5      37.1      ND      ND      Paroxysmal       7
  Wang (Persistent AF) \[[@b73-medscimonitbasicres-23-179]\]                     2012   China         Cohort         30     25     53       52       73.3      76        ND      ND      Persistent       7
  Liu (Paroxysmal AF) \[[@b74-medscimonitbasicres-23-179]\]                      2011   China         Cohort         19     58     55       57       84.2      67        100     100     Paroxysmal       8
  Liu (Persistent AF) \[[@b74-medscimonitbasicres-23-179]\]                      2011   China         Cohort         17     27     55.2     50.9     88.2      81.5      100     100     Persistent       8
  Vizzardi \[[@b75-medscimonitbasicres-23-179]\]                                 2009   Italy         Cohort         46     60     69       69       59        63        ND      ND      Persistent       7
  Letsas \[[@b76-medscimonitbasicres-23-179]\]                                   2009   Germany       Cohort         28     44     53.3     55.8     86        77        ND      ND      Combined types   7
  Korantzopoulos \[[@b77-medscimonitbasicres-23-179]\]                           2005   Greece        Cohort         9      21     67       70       44.4      52.38     ND      ND      Persistent       8

###### 

Information about markers and these levels in each study

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                                                                   Markers                                 Levels
  ------------------------------------------------------------------------------ --------------------------------------- -------------------------------------------------
  **Occurrence of AF**                                                                                                   

  Balci (Male subjects) \[[@b8-medscimonitbasicres-23-179]\]                     MPV                                     MPV \[AF: 9.3±0.4 *vs.* SR: 8.65±0.3\]

  Balci (Female subjects) \[[@b8-medscimonitbasicres-23-179]\]                   MPV                                     MPV \[AF: 8.9±0.3 *vs.* SR: 9±0.2\]

  Gurses \[[@b9-medscimonitbasicres-23-179]\]                                    WBC                                     WBC \[AF: 7.6±3.3 *vs.* SR: 7.1±0.9\]

  Karatas \[[@b10-medscimonitbasicres-23-179]\]                                  PC, MPV, WBC, NLR, RDW, Hb              PC \[AF: 230±69.3 *vs.* SR: 240±77.5\]\
                                                                                                                         MPV \[AF: 9.5±1.7 *vs.* SR: 8.7±1\]\
                                                                                                                         WBC \[AF: 12.8±5.6 *vs.* SR: 11.9±4.4\]\
                                                                                                                         NLR \[AF: 6.3±6.3 *vs.* SR: 5.1±4.7\]\
                                                                                                                         RDW \[AF: 13.9±1.7 *vs.* SR: 13.4±1.4\]\
                                                                                                                         Hb \[AF: 13.8±1.7 *vs.* SR: 13.9±1.6\]

  Korantzopoulos \[[@b11-medscimonitbasicres-23-179]\]                           WBC, RDW, Hb                            WBC \[AF: 6.46±0.35 *vs.* SR: 7.21±0.8\]\
                                                                                                                         RDW \[AF: 14.6±0.45 *vs.* SR: 13.77±0.22\]\
                                                                                                                         Hb \[AF: 13.05±0.50 *vs.* SR: 13.35±0.60\]

  Akdag \[[@b12-medscimonitbasicres-23-179]\]                                    PC, MPV, WBC, NLR, Hb                   PC \[AF: 265.6±73.4 *vs.* SR: 248.2±67.2\]\
                                                                                                                         MPV \[AF: 8.9±1.1 *vs.* SR: 7.8±1\]\
                                                                                                                         WBC \[AF: 7.3±1.9 *vs.* SR: 6.9 ±1.8\]\
                                                                                                                         NLR \[AF: 3.6±1.5 *vs.* SR: 2.9±1.3\]\
                                                                                                                         Hb \[AF: 14.3±1.1 *vs.* SR: 14.5±1\]

  Akyuz \[[@b13-medscimonitbasicres-23-179]\]                                    PC, MPV, Hb                             PC \[AF: 277±79 *vs.* SR: 264±82\]\
                                                                                                                         MPV \[AF: 9.8±0.6 *vs.* SR: 8.4±0.6\]\
                                                                                                                         Hb \[AF: 12.7±1.3 *vs.* SR: 13.1±1.4\]

  Chavaria \[[@b14-medscimonitbasicres-23-179]\]                                 PC, WBC, NLR, Hb                        PC \[AF: 242.2±54.1 *vs.* SR: 243.2±66.2\]\
                                                                                                                         WBC \[AF: 12.4±3.9 *vs.* SR: 11±3.59\]\
                                                                                                                         NLR \[AF: 3.55±3.15 *vs.* SR: 4.19±3.55\]\
                                                                                                                         Hb \[AF: 14±1.7 *vs.* SR: 14.3±1.7\]

  Drabik (Persistent AF) \[[@b15-medscimonitbasicres-23-179]\]                   PC, WBC                                 PC \[AF: 202±20.5 *vs.* SR: 219±16.5\]\
                                                                                                                         WBC \[AF: 7.3±0.6 *vs.* SR: 6.45±0.7\]

  Drabik (Paroxysmal AF) \[[@b15-medscimonitbasicres-23-179]\]                   PC, WBC                                 PC \[AF: 210.25±15.75 *vs.* SR: 219±16.5\]\
                                                                                                                         WBC \[AF: 6.07±0.42 *vs.* SR: 6.45±0.7\]

  Acet (Paroxysmal AF) \[[@b16-medscimonitbasicres-23-179]\]                     PC, WBC, NLR, Hb                        PC \[AF: 248.9±59 *vs.* SR: 259.8±95.9\]\
                                                                                                                         WBC \[AF: 11.5±2.5 *vs.* SR: 9.8±2\]\
                                                                                                                         NLR \[AF: 2.5 ±0.6 *vs.* SR: 1.8±0.4\]\
                                                                                                                         Hb \[AF: 13.8±1.7 *vs.* SR: 13.3±1.6\]

  Acet (Persistent and permanent AF) \[[@b16-medscimonitbasicres-23-179]\]       PC, WBC, NLR, Hb                        PC \[AF: 268.6±98 *vs.* SR: 259.8±95.9\]\
                                                                                                                         WBC \[AF: 10.9±2 *vs.* SR: 9.8±2\]\
                                                                                                                         NLR \[AF: 3.4±0.6 *vs.* SR: 1.8±0.4\]\
                                                                                                                         Hb \[AF: 13.9±1.7 *vs.* SR: 13.3±1.6\]

  Arik (effective INR) \[[@b17-medscimonitbasicres-23-179]\]                     PC, MPV, PDW, WBC, Hb                   PC \[AF: 258.25±53.83 *vs.* SR: 255.75±41.5\]\
                                                                                                                         MPV \[AF: 7.56±0.63 *vs.* SR: 7.63±0.68\]\
                                                                                                                         PDW \[AF: 17.05±0.86 *vs.* SR: 17.52±0.71\]\
                                                                                                                         WBC \[AF: 7.47±1.23 *vs.* SR: 7.38±1.11\]\
                                                                                                                         Hb \[AF: 12.95±0.96 *vs.* SR: 13.47±0.75\]

  Arik (ineffective INR) \[[@b17-medscimonitbasicres-23-179]\]                   PC, MPV, PDW, WBC, Hb                   PC \[AF: 238.75±41.16 *vs.* SR: 255.75±41.5\]\
                                                                                                                         MPV \[AF: 8.26±0.63 *vs.* SR: 7.63±0.68\]\
                                                                                                                         PDW \[AF: 17.50±1.13 *vs.* SR: 17.52±0.71\]\
                                                                                                                         WBC \[AF: 7.49±1.21 *vs.* SR: 7.38±1.11\]\
                                                                                                                         Hb \[AF: 12.95±0.81 *vs.* SR: 13.47±0.75\]

  Distelmaier \[[@b18-medscimonitbasicres-23-179]\]                              PC, WBC, RBC, RDW, MCV, MCHC, HCT, Hb   PC \[AF: 202±14.75 *vs.* SR: 215±14.16\]\
                                                                                                                         WBC \[AF: 9.96±1.42 *vs.* SR: 9.18±0.88\]\
                                                                                                                         RBC \[AF: 4.57±0.22 *vs.* SR: 4.23±0.12\]\
                                                                                                                         RDW \[AF: 13.9±0.3 *vs.* SR: 13.62±0.25\]\
                                                                                                                         MCV \[AF: 90.5±1.67 *vs.* SR: 90.78±0.82\]\
                                                                                                                         MCHC \[AF: 33.87±0.35 *vs.* SR: 33.47±0.28\]\
                                                                                                                         HCT \[AF: 41.07±1.92 *vs.* SR: 38.4±1.13\]\
                                                                                                                         Hb \[AF: 13.95±0.65 *vs.* SR: 12.85±0.35\]

  Erdogan (with normal ventricular rate) \[[@b19-medscimonitbasicres-23-179]\]   PC, MPV, WBC, HCT, Hb                   PC \[AF: 245.6±114.9 *vs.* SR: 238.4±66.6\]\
                                                                                                                         MPV \[AF: 7.82±1.2 *vs.* SR: 7.68±0.70\]\
                                                                                                                         WBC \[AF: 7.52±2.06 *vs.* SR: 7.55±1.89\]\
                                                                                                                         HCT \[AF: 39.7±5.2 *vs.* SR: 40.3±3.4\]\
                                                                                                                         Hb \[AF: 14±1.9 *vs.* SR: 13.9±1.3\]

  Erdogan (with high ventricular rate) \[[@b19-medscimonitbasicres-23-179]\]     PC, MPV, WBC, HCT, Hb                   PC \[AF: 225.5±76.3 *vs.* SR: 238.4±66.6\]\
                                                                                                                         MPV \[AF: 8.05±0.6 *vs.* SR: 7.68±0.70\]\
                                                                                                                         WBC \[AF: 7.47±1.47 *vs.* SR: 7.55±1.89\]\
                                                                                                                         HCT \[AF: 40.7±3.8 *vs.* SR: 40.3±3.4\]\
                                                                                                                         Hb \[AF: 14.3±1.3 *vs.* SR: 13.9±1.3\]

  Zheng \[[@b20-medscimonitbasicres-23-179]\]                                    WBC                                     WBC \[AF: 5.6±1.14 *vs.* SR: 5.46±1.21\]

  Xu (without thrombotic events) \[[@b21-medscimonitbasicres-23-179]\]           PC, MPV, Hb                             PC \[AF: 205±31 *vs.* SR: 209±41\]\
                                                                                                                         MPV \[AF: 10.6±1.9 *vs.* SR: 8.7±0.8\]\
                                                                                                                         Hb \[AF: 14.5±1.4 *vs.* SR: 14.6±1.1\]

  Xu (with thrombotic events) \[[@b21-medscimonitbasicres-23-179]\]              PC, MPV, Hb                             PC \[AF: 206±42 *vs.* SR: 209±41\]\
                                                                                                                         MPV \[AF: 11.7±2 *vs.* SR: 8.7±0.8\]\
                                                                                                                         Hb \[AF: 14.6±1.3 *vs.* SR: 14.6±1.1\]

  Gungor \[[@b22-medscimonitbasicres-23-179]\]                                   PC, MPV, WBC, NLR, RDW, MCV, Hb         PC \[AF: 249.4±59.4 *vs.* SR: 253.4±61.1\]\
                                                                                                                         MPV \[AF: 8.99±0.65 *vs.* 9.14±0.98\]\
                                                                                                                         WBC \[AF: 7.21±1.62 *vs.* SR: 6.81±1.17\]\
                                                                                                                         NLR \[AF: 2.04±0.94 *vs.* SR: 1.93±0.64\]\
                                                                                                                         RDW \[AF: 13.45±0.2 *vs.* SR: 12.57±0.27\]\
                                                                                                                         MCV \[AF: 90.2±5.4 *vs.* SR: 89.2±3.6\]\
                                                                                                                         Hb \[AF: 14.5±1.4 *vs.* SR: 14.2±1.2\]

  Liu \[[@b23-medscimonitbasicres-23-179]\]                                      RDW                                     RDW \[AF: 12.71±0.9 *vs.* SR: 12.45±0.62\]

  Sarikaya \[[@b24-medscimonitbasicres-23-179]\]                                 RDW, Hb                                 RDW \[AF: 15.13±1.58 *vs.* 14.05±1.15\]\
                                                                                                                         Hb \[AF: 13.74±1.38 *vs.* SR: 13.88±1.62\]

  Sonmez \[[@b25-medscimonitbasicres-23-179]\]                                   PC, NLR, Hb                             PC \[AF: 231±60 *vs.* 247±67\]\
                                                                                                                         NLR \[AF: 2.7±1.1 *vs.* SR: 2.1±1\]\
                                                                                                                         Hb \[AF: 13.3±1.6 *vs.* SR: 13.1±1.8\]

  Ulu \[[@b26-medscimonitbasicres-23-179]\]                                      PC, PDW, MPV                            PC \[AF: 236.44±63.92 *vs.* SR: 233.32±86.24\]\
                                                                                                                         PDW \[AF: 12.64±1.43 *vs.* SR: 11.76±1.41\]\
                                                                                                                         MPV \[AF: 11.47±0.93 *vs.* SR: 10.37±1.07\]

  Berge \[[@b27-medscimonitbasicres-23-179]\]                                    PC, Hb                                  PC \[AF: 230±7.5 *vs.* SR: 261.25±4.16\]\
                                                                                                                         Hb \[AF: 14.6±0.2 *vs.* SR: 14.7±0.06\]

  Ertas (without stroke) \[[@b28-medscimonitbasicres-23-179]\]                   PC, WBC, NLR, RDW, Hb                   PC \[AF: 232±55 *vs.* SR: 258±54\]\
                                                                                                                         WBC \[AF: 7.8±1.8 *vs.* SR: 7±1.4\]\
                                                                                                                         NLR \[AF: 3.1±2.1 *vs.* SR: 2.05±0.9\]\
                                                                                                                         RDW \[AF: 14.3±1.8 *vs.* SR: 13.2±0.9\]\
                                                                                                                         Hb \[AF: 13±1.4 *vs.* SR: 14±1.7\]

  Ertas (with stroke) \[[@b28-medscimonitbasicres-23-179]\]                      PC, WBC, NLR, RDW, Hb                   PC \[AF: 240±82 *vs.* SR: 258±54\]\
                                                                                                                         WBC \[AF: 8.6±2.8 *vs.* SR: 7±1.4\]\
                                                                                                                         NLR \[AF: 5.6±3.4 *vs.* SR: 2.05±0.9\]\
                                                                                                                         RDW \[AF: 14.1±1.7 *vs.* SR: 13.2±0.9\]\
                                                                                                                         Hb \[AF: 13±1.6 *vs.* SR: 14±1.7\]

  Gungor \[[@b29-medscimonitbasicres-23-179]\]                                   WBC, Hb                                 WBC \[AF: 6.5±1.5 *vs.* SR: 6.2±1.1\]\
                                                                                                                         Hb \[AF: 14.7±1.5 *vs.* SR: 14.9±1.3\]

  Turgut \[[@b30-medscimonitbasicres-23-179]\]                                   PC, MPV                                 PC \[AF: 274±82 *vs.* SR: 253±83\]\
                                                                                                                         MPV \[AF: 9±0.2 *vs.* SR: 8.4±0.2\]

  Jaremo (healthy control) \[[@b31-medscimonitbasicres-23-179]\]                 PC                                      PC \[AF: 241±64 *vs.* 260±78\]

  Jaremo (disease control) \[[@b31-medscimonitbasicres-23-179]\]                 PC                                      PC \[AF: 241±64 *vs.* 265±84\]

  Sahin \[[@b32-medscimonitbasicres-23-179]\]                                    MPV, WBC, NLR                           MPV \[AF: 8.31±1.12 *vs.* SR: 7.99±1.39\]\
                                                                                                                         WBC \[AF: 7.86±2.04 *vs.* 7.67±2.03\]\
                                                                                                                         NLR \[AF: 2.87±1.3 *vs.* 2.2±1.56\]

  Tekin \[[@b33-medscimonitbasicres-23-179]\]                                    PC, MPV, WBC, HCT                       PC \[AF: 242±90 *vs.* 243±67\]\
                                                                                                                         MPV \[AF: 9.49±1.08 *vs.* 9.09±1.13\]\
                                                                                                                         WBC \[AF: 7.48±2.15 *vs.* 6.94±1.68\]\
                                                                                                                         HCT \[AF: 40.22±4.8 *vs.* 41.45±4.79\]

  Turfan (without stroke) \[[@b34-medscimonitbasicres-23-179]\]                  PC, MPV, Hb                             PC \[AF: 264±94 *vs.* 213±72\]\
                                                                                                                         MPV \[AF: 9.1±1 *vs.* 8.6±1.3\]\
                                                                                                                         Hb \[AF: 12.8±1.1 *vs.* 12.7±1.2\]

  Turfan (with stroke) \[[@b34-medscimonitbasicres-23-179]\]                     PC, MPV, Hb                             PC \[AF: 245±73 *vs.* 213±72\]\
                                                                                                                         MPV \[AF: 9.7±0.9 *vs.* 8.6±1.3\]\
                                                                                                                         Hb \[AF: 13±1.4 *vs.* 12.7±1.2\]

  Feng \[[@b35-medscimonitbasicres-23-179]\]                                     PC, MPV, WBC, RBC, MCV                  PC \[AF: 213.3±82.5 *vs.* SR: 217.6±81.9\]\
                                                                                                                         MPV \[AF: 9.95±1.32 *vs.* SR: 9.02±1.16\]\
                                                                                                                         WBC \[AF: 6.91±3.24 *vs.* SR: 6.88±3.35\]\
                                                                                                                         RBC \[AF: 4.47±0.68 *vs.* 4.56±0.71\]\
                                                                                                                         MCV \[AF: 93.8±5.2 *vs.* 94.1±5.3\]

  Liu (Paroxysmal AF) \[[@b36-medscimonitbasicres-23-179]\]                      WBC                                     WBC \[AF: 6.76±1.85 *vs.* SR: 6.34±1.89\]

  Liu (Persistent AF) \[[@b36-medscimonitbasicres-23-179]\]                      WBC                                     WBC \[AF: 6.37±1.66 *vs.* SR: 6.34±1.89\]

  Yoshizaki \[[@b37-medscimonitbasicres-23-179]\]                                WBC                                     WBC \[AF: 11.1±5.2 *vs.* SR: 10.6±4\]

  Hayashi (Paroxysmal AF) \[[@b38-medscimonitbasicres-23-179]\]                  PC, WBC                                 PC \[AF: 260±83 *vs.* SR: 190±77\]\
                                                                                                                         WBC \[AF: 5.8±4.2 *vs.* SR: 5.3±3\]

  Hayashi (Chronic AF) \[[@b38-medscimonitbasicres-23-179]\]                     PC, WBC                                 PC \[AF: 200±14 *vs.* SR: 190±77\]\
                                                                                                                         WBC \[AF: 5.6±3.8 *vs.* SR: 5.3±3\]

  Fu \[[@b39-medscimonitbasicres-23-179]\]                                       PC                                      PC \[AF: 210±55.5 *vs.* SR: 221.1±51.1\]

  Liu \[[@b40-medscimonitbasicres-23-179]\]                                      WBC                                     WBC \[AF: 6.5±1.9 *vs.* SR: 7.2±2.2\]

  Letsas (Paroxysmal AF) \[[@b41-medscimonitbasicres-23-179]\]                   WBC                                     WBC \[AF: 7.7±2.19 *vs.* SR: 7.15±1.87\]

  Letsas (Permanent AF) \[[@b41-medscimonitbasicres-23-179]\]                    WBC                                     WBC \[AF: 6.97±1.9 *vs.* SR: 7.15±1.87\]

  Luan (Persistent AF) \[[@b42-medscimonitbasicres-23-179]\]                     WBC                                     WBC \[AF: 6.13±1.66 *vs.* SR: 6.13±1.95\]

  Luan (Paroxysmal AF) \[[@b42-medscimonitbasicres-23-179]\]                     WBC                                     WBC \[AF: 6.9±1.28 *vs.* SR: 6.13±1.95\]

  Alberti \[[@b43-medscimonitbasicres-23-179]\]                                  PC, WBC                                 PC \[AF: 185.6±10 *vs.* SR: 243.3±9.4\]\
                                                                                                                         WBC \[AF: 5.6±0.3 *vs.* SR: 6.3±0.3\]

  Dai \[[@b44-medscimonitbasicres-23-179]\]                                      WBC                                     WBC \[AF: 7.32±1.89 *vs.* SR: 6.57±1.91\]

  Ichiki \[[@b45-medscimonitbasicres-23-179]\]                                   WBC                                     WBC \[AF: 4.6±0.3 *vs.* SR: 5.3±0.5\]

  Yao (Persistent AF) \[[@b46-medscimonitbasicres-23-179]\]                      WBC                                     WBC \[AF: 5.76±0.28 *vs.* SR: 5.69±0.35\]

  Yao (Paroxysmal AF) \[[@b46-medscimonitbasicres-23-179]\]                      WBC                                     WBC \[AF: 5.69±0.31 *vs.* SR: 5.69±0.35\]

  Colkesen \[[@b47-medscimonitbasicres-23-179]\]                                 PC, MPV, WBC                            PC \[AF: 242±13 *vs.* SR: 236±53\]\
                                                                                                                         MPV \[AF: 10±2 *vs.* SR: 8.3±1.50\]\
                                                                                                                         WBC \[AF: 7.58±2.35 *vs.* SR: 7.47±2.08\]

  Choudhury (disease control) \[[@b48-medscimonitbasicres-23-179]\]              PC, MPV, WBC, HCT, Hb                   PC \[AF: 259.9±66.3 *vs.* SR: 261.1±63.4\]\
                                                                                                                         MPV \[AF: 7.6±1.4 *vs.* SR: 7.8±1.9\]\
                                                                                                                         WBC \[AF: 7.1±1.8 *vs.* SR: 7.1±2.2\]\
                                                                                                                         HCT \[AF: 42.3±4.3 *vs.* SR: 41.6±3.9\]\
                                                                                                                         Hb \[AF: 14.6±1.6 *vs.* SR: 13.9±1.5\]

  Choudhury (healthy control) \[[@b48-medscimonitbasicres-23-179]\]              PC, MPV, WBC, HCT, Hb                   PC \[AF: 259.9±66.3 *vs.* SR: 266.9±56.1\]\
                                                                                                                         MPV \[AF: 7.6±1.4 *vs.* SR: 7.4±0.97\]\
                                                                                                                         WBC \[AF: 7.1±1.8 *vs.* SR: 6.4±1.8\]\
                                                                                                                         HCT \[AF: 42.3±4.3 *vs.* SR: 40.6±33.7\]\
                                                                                                                         Hb \[AF: 14.6±1.6 *vs.* SR: 14.1±1.2\]

  Pirat \[[@b49-medscimonitbasicres-23-179]\]                                    WBC                                     WBC \[AF: 7.45±1.59 *vs.* SR: 6.7±0.98\]

  Yip \[[@b50-medscimonitbasicres-23-179]\]                                      PC, WBC                                 PC \[AF: 204±57 *vs.* SR: 209±49\]\
                                                                                                                         WBC \[AF: 6.7±1.5 *vs.* SR: 6.6±1.7\]

  Kamath (Paroxysmal and persistent AF) \[[@b51-medscimonitbasicres-23-179]\]    PC, HCT                                 PC \[AF: 280±81 *vs.* SR: 253±51\]\
                                                                                                                         HCT \[AF: 45±4 *vs.* SR: 42±3\]

  Kamath (Permanent AF) \[[@b51-medscimonitbasicres-23-179]\]                    PC, HCT                                 PC \[AF: 264±75 *vs.* SR: 253±51\]\
                                                                                                                         HCT \[AF: 43±5 *vs.* SR: 42±3\]

  Kamath (Paroxysmal AF) \[[@b52-medscimonitbasicres-23-179]\]                   PC, HCT                                 PC \[AF: 279±73 *vs.* SR: 252±53\]\
                                                                                                                         HCT \[AF: 43±5 *vs.* SR: 42±3\]

  Kamath (Permanent AF) \[[@b52-medscimonitbasicres-23-179]\]                    PC, HCT                                 PC \[AF: 266±76 *vs.* SR: 252±53\]\
                                                                                                                         HCT \[AF: 43±5 *vs.* SR: 42±3\]

  Kamath \[[@b53-medscimonitbasicres-23-179]\]                                   PC                                      PC \[AF: 253±77 *vs.* SR: 261±62\]

  Kamath \[[@b54-medscimonitbasicres-23-179]\]                                   PC                                      PC \[AF: 253±67 *vs.* SR: 270±49\]

  Peverill \[[@b55-medscimonitbasicres-23-179]\]                                 PC, MPV, MCV, HCT                       PC \[AF: 218±55 *vs.* SR: 241±59\]\
                                                                                                                         MPV \[AF: 9.7±1.4 *vs.* SR: 9.9±1.4\]\
                                                                                                                         MCV \[AF: 89±6 *vs.* SR: 88±7\]\
                                                                                                                         HCT \[AF: 42±5 *vs.* SR: 39±4\]

  Kahn (without stroke) \[[@b56-medscimonitbasicres-23-179]\]                    PC, Hb                                  PC \[AF: 230±98 *vs.* SR: 233±49\]\
                                                                                                                         Hb \[AF: 14.9±1.3 *vs.* SR: 13.4±1.5\]

  Kahn (with stroke) \[[@b56-medscimonitbasicres-23-179]\]                       PC, Hb                                  PC \[AF: 253±82 *vs.* SR: 242±77\]\
                                                                                                                         Hb \[AF: 14.1±1.2 *vs.* SR: 14.3±1.7\]

  Lip \[[@b57-medscimonitbasicres-23-179]\]                                      PC                                      PC \[AF: 242±67 *vs.* SR: 224±63\]

  Gustafsson (without stroke) \[[@b58-medscimonitbasicres-23-179]\]              PC                                      PC \[AF: 172.25±8.75 *vs.* SR: 234.75±10.75\]

  Gustafsson (with stroke) \[[@b58-medscimonitbasicres-23-179]\]                 PC                                      PC \[AF: 179±18.5 *vs.* SR: 234.75±10.75\]

  **Recurrence of AF**                                                                                                   

  Gurses \[[@b9-medscimonitbasicres-23-179]\]                                    WBC                                     WBC \[AF: 7.5±3.9 *vs.* SR: 7.6±3.2\]

  Hongliang Li \[[@b59-medscimonitbasicres-23-179]\]                             PC, WBC, RDW, Hb                        PC \[AF: 219.77±44.15 *vs.* SR: 199.32±52.58\]\
                                                                                                                         WBC \[AF: 6.51±1.84 *vs.* SR: 7.41±14.65\]\
                                                                                                                         RDW \[AF: 12.81±0.94 *vs.* SR: 12.37±0.56\]\
                                                                                                                         Hb \[AF: 14.11±1.85 *vs.* SR: 13.94±1.21\]

  Yanagisawa (without heart failure) \[[@b60-medscimonitbasicres-23-179]\]       WBC, RDW, MCV, Hb                       WBC \[AF: 5.5±1.4 *vs.* SR: 5.3±1.6\]\
                                                                                                                         RDW \[AF: 13.3±0.8 *vs.* SR: 13.2±0.8\]\
                                                                                                                         MCV \[AF: 92.3±4.4 *vs.* SR: 92±4.2\]\
                                                                                                                         Hb \[AF: 14±1.5 *vs.* SR: 14±1.5\]

  Yanagisawa (with heart failure) \[[@b60-medscimonitbasicres-23-179]\]          WBC, RDW, MCV, Hb                       WBC \[AF: 5.7±1.5 *vs.* SR: 6.1±1.6\]\
                                                                                                                         RDW \[AF: 14.5±2 *vs.* SR: 13.5±0.9\]\
                                                                                                                         MCV \[AF: 91.3±6.4 *vs.* SR: 92.3±4.6\]\
                                                                                                                         Hb \[AF: 13.3±2.3 *vs.* SR: 14.1±1.8\]

  Aksu \[[@b61-medscimonitbasicres-23-179]\]                                                                             MPV \[AF: 8.81±1.4 *vs.* SR: 8.7±1.88\]\
                                                                                                                         WBC \[AF: 6.97±1.6 *vs.* SR: 7.38±1.7\]\
                                                                                                                         NLR \[AF: 2.5±0.78 *vs.* SR: 1.83±0.63\]\
                                                                                                                         RDW \[AF: 16.1±1.44 *vs.* SR: 14.87±0.48\]\
                                                                                                                         WBC \[AF: 13.3±1.34 *vs.* SR: 13.72±1.17\]

  Gurses \[[@b62-medscimonitbasicres-23-179]\]                                   PC, WBC, RDW, Hb                        PC \[AF: 221.8±56.3 *vs.* SR: 228.4±68.8\]\
                                                                                                                         WBC \[AF: 7.82±2.43 *vs.* SR: 7.44±1.89\]\
                                                                                                                         RDW \[AF: 14.3±0.93 *vs.* SR: 13.52±0.93\]\
                                                                                                                         Hb \[AF: 14.19±1.85 *vs.* SR: 13.92±1.76\]

  Karavelioglu \[[@b63-medscimonitbasicres-23-179]\]                             PC, WBC, NLR, HCT, Hb                   PC \[AF: 234±65.1 *vs.* SR: 258.1±93.4\]\
                                                                                                                         WBC \[AF: 7.6±2.64 *vs.* SR: 7.93±2.42\]\
                                                                                                                         NLR \[AF: 2.8±1.59 *vs.* SR: 2.13±1.04\]\
                                                                                                                         HCT \[AF: 40.1±5.1 *vs.* SR: 41.1±5.2\]\
                                                                                                                         Hb \[AF: 13.6±2.9 *vs.* SR: 13.8±2.9\]

  Wen \[[@b64-medscimonitbasicres-23-179]\]                                      PC, WBC, NLR, Hb                        PC \[AF: 196±59 *vs.* SR: 198±44\]\
                                                                                                                         WBC \[AF: 6.36±1.56 *vs.* SR: 5.63±1.2\]\
                                                                                                                         NLR \[AF: 2.16±1.23 *vs.* SR: 1.94±0.94\]\
                                                                                                                         Hb \[AF: 12.6±1.8 *vs.* SR: 13.1±1.7\]

  Guo Xueyuan \[[@b65-medscimonitbasicres-23-179]\]                              WBC, NLR, Hb                            WBC \[AF: 8.17±1.7 *vs.* SR: 7.84±1.6\]\
                                                                                                                         NLR \[AF: 1.9±1.19 *vs.* SR: 1.81±0.1\]\
                                                                                                                         Hb \[AF: 14.84±1.57 *vs.* SR: 14.52±1.82\]

  Aribas \[[@b66-medscimonitbasicres-23-179]\]                                   WBC, NLR                                WBC \[AF: 7.4±2 *vs.* SR: 7.6±2\]\
                                                                                                                         NLR \[AF: 2.38±2.09 *vs.* SR: 2.23±1.23\]

  Bing Li \[[@b67-medscimonitbasicres-23-179]\]                                  WBC                                     WBC \[AF: 6.7±2.2 *vs.* SR: 6.1±2\]

  Canpolat \[[@b68-medscimonitbasicres-23-179]\]                                 WBC, NLR, Hb                            WBC \[AF: 8.94±2.08 *vs.* SR: 7.46±2.34\]\
                                                                                                                         NLR \[AF: 3.53±0.95 *vs.* SR: 2.65±0.23\]\
                                                                                                                         Hb \[AF: 13.5±1.8 *vs.* SR: 13.6±1.9\]

  Im \[[@b69-medscimonitbasicres-23-179]\]                                       NLR                                     NLR \[AF: 1.9±1.2 *vs.* SR: 2±2.14\]

  Xiao-nan HE \[[@b70-medscimonitbasicres-23-179]\]                              WBC                                     WBC \[AF: 6.2±1.8 *vs.* SR: 6.5±1.9\]

  Ferro \[[@b71-medscimonitbasicres-23-179]\]                                    WBC                                     WBC \[AF: 7.44±1.45 *vs.* SR: 7.47±1.71\]

  Smit \[[@b72-medscimonitbasicres-23-179]\]                                     WBC                                     WBC \[AF: 7.7±1.5 *vs.* SR: 7.6±2\]

  Wang (Paroxysmal AF) \[[@b73-medscimonitbasicres-23-179]\]                     WBC                                     WBC \[AF: 6.1±1.4 *vs.* SR: 6.1±1.4\]

  Wang (Persistent AF) \[[@b73-medscimonitbasicres-23-179]\]                     WBC                                     WBC \[AF: 6.2±1.9 *vs.* SR: 6.6±1.5\]

  Liu (Paroxysmal AF) \[[@b74-medscimonitbasicres-23-179]\]                      WBC                                     WBC \[AF: 6.2±2.9 *vs.* SR: 5.9±1.4\]

  Liu (Persistent AF) \[[@b74-medscimonitbasicres-23-179]\]                      WBC                                     WBC \[AF: 5.6±1.4 *vs.* SR: 6±2.4\]

  Vizzardi \[[@b75-medscimonitbasicres-23-179]\]                                 WBC                                     WBC \[AF: 6.9±1.4 *vs.* SR: 7±5.4\]

  Letsas \[[@b76-medscimonitbasicres-23-179]\]                                   WBC                                     WBC \[AF: 6.86±1.21 *vs.* SR: 5.79±1.39\]

  Korantzopoulos \[[@b77-medscimonitbasicres-23-179]\]                           WBC                                     WBC \[AF: 7.29±1.84 *vs.* SR: 6.64±1.39\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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